Cover Page for Protocol 
 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9924-4224 
Official title of study: PI[INVESTIGATOR_15597] 4 – vs. GLP-1 RA 
Efficacy and safety of oral semaglutide versus liraglutide and 
versus placebo in subjects wit h type 2 diabetes mellitus 
A 52-week randomised, double- blind, active- and placebo- 
controlled trial 
Document date: [ADDRESS_35995] of contents
Protocol ....................................................... ............................................................... .........................
Protocol amendment 1 ........................................... ............................................................... .............CONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide
Trial ID: NN9924-4224Clinical Trial Report
Appendix 16.1.129 October 2018
1.0
Final
16.1.1 Protocol and protocol amendmentsCONFIDENTIAL
Redacted protocol 
Lncludes redaction of personal identifiable DQGFRPSDQ\
FRQILGHQWLDO information. 
. 
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 1 of 132
Protocol
Trial ID: NN9924-4224
PI[INVESTIGATOR_15597] 4 – vs. GLP-1 RA
Efficacy and Safety of Oral Semaglutide versus Liraglutide 
and versus Placebo in Subjects with Type 2 Diabetes Mellitus
A 52-week randomised, double-blind, active- and placebo-controlled trial
Trial phase: 3a
Protocol originator
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_35996] of abbreviations.......................................................................................................... ...............................8
1 Summary....................................................................................................................... ...........................11
Primary objective.............................................................................................................. ...........11
Secondary objectives ........................................................................................................... ........11
Primary endpoint............................................................................................................... ...........11
Key secondary endpoints...........................................................................................11
2 Flow chart .................................................................................................................... ............................15
3 Background information and rationale for the trial............................................................................ 22
3.1 Background information...................................................................................................... ........22
3.1.1 Type 2 diabetes mellitus ............................................................................................22
3.1.2 Glucagon-like peptide-1 ............................................................................................22
3.1.3 Oral semaglutide........................................................................................................22
3.1.4 Nonclinical data .........................................................................................................2 3
[IP_ADDRESS] Semaglutide.........................................................................................23
[IP_ADDRESS] SNAC ..................................................................................................24
3.1.5 Clinical data for or al semaglutide..............................................................................25
[IP_ADDRESS] Pharmacokinetics ................................................................................25
[IP_ADDRESS] Efficacy ...............................................................................................[IP_ADDRESS] Safety...................................................................................................26
3.1.6 Liraglutide............................................................................................................... ...27
3.2 Rationale for the trial ..................................................................................................... ..............27
4 Objectives and endpoints...................................................................................................... ..................28
4.1 Objectives .................................................................................................................. ..................28
4.1.1 Primary objective.......................................................................................................28
4.1.2 Secondary objectives .................................................................................................28
4.2 Endpoints ................................................................................................................... ..................28
4.2.1 Primary endpoint........................................................................................................28
4.2.2 Secondary endpoints..................................................................................................28
[IP_ADDRESS] Confirmatory seconda ry endpoints .....................................................28
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................[ADDRESS_35997] ..........................................................................35CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_35998] administration........................................................43
8.1.4 Phone contacts ...........................................................................................................4 4
8.1.5 End-of-treatment (visit 13) and Follow-up (visit 14).................................................[ADDRESS_35999] and Follow-up (visits 13A and 14A)......[ADDRESS_36000] related infor mation/assessments ..................................................................................... 46
8.2.1 Demography...............................................................................................................4 6
8.2.2 Diabetes history a nd diabetes co mplications .............................................................46
8.2.3 Concomitant illness a nd medical history ...................................................................46
8.2.4 Concomitant medication............................................................................................478.2.5 Childbearing potential................................................................................................48
8.2.6 Tobacco use ............................................................................................................... 48
8.3 Efficacy assessments........................................................................................................ ............48
8.3.1 Laboratory assessmen ts for efficacy..........................................................................48
[IP_ADDRESS] Fasting plasma glucose........................................................................[ADDRESS_36001] circumference ..................................................................................................50
8.3.5 Patient reported outcomes questionnaires..................................................................51
8.4 Safety assessments.......................................................................................................... .............51
8.4.1 Adverse events...........................................................................................................5 1
[IP_ADDRESS] Medication error..................................................................................51
[IP_ADDRESS] Adverse events requiring additional data collection ...........................52
8.4.2 Physical examination .................................................................................................53
8.4.3 Vital signs ............................................................................................................... ...53
8.4.4 Eye examination ........................................................................................................53
8.4.5 Electrocardiogram (12-lead) ......................................................................................548.4.6 Laboratory assessments for safety .............................................................................55
8.4.7 Pregnancy testing.......................................................................................................56
8.4.8 Anti-semaglutide antibodies ......................................................................................56
8.4.9 Hypoglycaemic epi[INVESTIGATOR_1841] ...........................................................................................56CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36002] compliance.......................................................................................................... ............60
9 Trial supplies ................................................................................................................ ...........................62
9.1 Trial products.............................................................................................................. .................62
9.2 Labelling ................................................................................................................... ...................63
9.3 Storage ..................................................................................................................... ....................64
9.4 Drug accountability and destruction ......................................................................................... ...65
9.5 Auxiliary supplies.......................................................................................................... ..............65
10 Interactive voice/web response system ........................................................................................ ..........66
11 Randomisation procedure and b reaking of blinded codes ..................................................................67
11.1 Breaking of blinded codes .................................................................................................. .........67
12 Adverse events, technical comp laints and pregnancies .......................................................................68
12.1 Definitions ................................................................................................................ ...................68
12.1.1 Adverse event ............................................................................................................ 68
12.1.2 Serious adverse event.................................................................................................69
12.1.3 Non-serious adverse event .........................................................................................70
12.1.4 Medication errors.......................................................................................................7 1
12.1.5 Adverse events requiring additional data collection..................................................7112.1.6 Technical complaints .................................................................................................72
12.2 Reporting of adverse events................................................................................................ .........73
12.3 Follow-up of adverse events ................................................................................................ ........76
12.4 Technical complaints and tec hnical complaint samples ..............................................................77
12.4.1 Reporting of technical complaints .............................................................................7712.4.2 Collection, storage and shipment of technical complaint samples ............................77
12.5 Pregnancies in female subjects ............................................................................................. .......78
12.5.1 Pregnancies in female subjects ..................................................................................78
12.6 Precautions and/or overdose ................................................................................................ ........79
12.7 Committees related to safety............................................................................................... .........80
12.7.1 Novo Nordisk sa fety committee ................................................................................80
12.7.2 Event adjudication committee....................................................................................80
13 Case report forms............................................................................................................ ........................85
13.1 Corrections to cas e report forms........................................................................................... .......85
13.2 Case report form flow...................................................................................................... ............85
14 Monitoring procedures ........................................................................................................ ...................87
15 Data management.............................................................................................................. ......................89
16 Computerised systems......................................................................................................... ....................90
17 Statistical considerations ................................................................................................... .....................91
17.1 Sample size calculation.................................................................................................... ............93
17.2 Definition of analysis sets................................................................................................ ............96
17.3 Primary endpoint........................................................................................................... ...............99
17.3.1 Primary analysis for the primary estimand ................................................................99CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 5 of 132
17.3.2 Primary analysis for th e secondary estimand...........................................................100
17.3.3 Sensitivity analyses..................................................................................................101
[IP_ADDRESS] Pattern mixture models......................................................................102
[IP_ADDRESS] Other sensitivity analyses..................................................................[ZIP_CODE].3.3.3 Assessment of sensitivity analyses....................................................103
17.4 Secondary endpoints........................................................................................................ ..........103
17.4.1 Confirmatory sec ondary endpoints..........................................................................103
17.4.2 Supportive seconda ry endpoints ..............................................................................104
[IP_ADDRESS] Efficacy endpoints.............................................................................[ZIP_CODE].4.2.2 Continuous efficacy  endpoints ..........................................................104
[IP_ADDRESS] Safety endpoints ................................................................................106
17.5 Interim analysis ........................................................................................................................110
17.6 Health economics and/or patien t reported outco mes (PROs) ....................................................111
18 Ethics ....................................................................................................................... ...............................112
18.1 Benefit-risk assessment of the trial....................................................................................... .....112
18.1.1 Risks and precautions ..............................................................................................112
[IP_ADDRESS] Liraglutide .........................................................................................114
[IP_ADDRESS] Placebo ..............................................................................................114
18.1.2 Benefits................................................................................................................. ...115
18.1.3 Risk and benefit conclusion.....................................................................................115
18.2 Informed consent ........................................................................................................... ............115
18.3 Data handling.............................................................................................................. ...............116
18.4 Information to subjects during trial....................................................................................... .....116
18.5 Premature termination of the trial and/or trial site.....................................................................11 6
19 Protocol compliance.......................................................................................................... ....................118
19.1 Protocol deviations ........................................................................................................ ............118
19.2 Prevention of missing data................................................................................................. ........118
20 Audits and inspections ....................................................................................................... ...................119
21 Critical documents ........................................................................................................... .....................120
22 Responsibilities ............................................................................................................. .........................122
23 Reports and publications..................................................................................................... .................123
23.1 Communication of results................................................................................................... .......123
23.1.1 Authorship ................................ ...............................................................................124
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .........................................................124
23.2 Investigator access to data and review of results .......................................................................124
24 Retention of clinical trial docume ntation and human  biosamples....................................................125
24.1 Retention of clinical trial documentation.................................................................................. .125
24.2 Retention of human biosamples.............................................................................................. ...125
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............127
26 Indemnity statement .......................................................................................................... ...................128
27 References ................................................................................................................... ...........................129CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 6 of 132
Attachment I – Global list of key staff and relevant departments and suppliers
Attachment II – Country list of key staff and relevant departments
Appendix A – Monitoring of Calcitonin
Appendix B – Adverse events requiring additional data collectionCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 7 of 132
Table of Figures
Page
Figure 5–1 Trial design......................................................................................................... ....................31
Figure 12–1 Reporting of AEs.................................................................................................... ................75
Figure 17–1 Graphical illustration of the closed testing procedure ............................................................96
Figure 17–2 ADA classification of hypoglycaemia................................................................................ ..110
Table of Tables
Page
Table 5–1 Treatment of subjects................................................................................................. .............34
Table 9–1 Investigati onal medicinal products.................................................................................... .....62
Table 9–2 Storage conditions for investigational medicinal products.....................................................64
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject to event 
adjudication ................................................................................................................... .........72
Table 12–2 Adverse events for adjudication ...................................................................................... .......82
Table 17–1 Assumptions used in  the sample s ize calculation ...................................................................95
Table 17–2 Calculated powers for individual hypotheses .........................................................................9 5CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36003] research organisationCVD cardiovascular diseaseDFU direction for useDPP-4 dipeptidyl peptidase-4DTSQ diabetes treatment satisfaction questionnaireDUN dispensing unit numberEAC event adjudication committeeECG electrocardiogrameCRF electronic case report formEDC electronic data captureeGFR estimated glomerular filtration rateEMA European Medicines AgencyEOT end of treatmentCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36004] visit
GCP Good Clinical Practice
GLP-1 glucagon-like peptide-1GLP-1 RA glucagon-like peptide-1 receptor agonistHbA
1c glycosylated haemoglobin
HDL high density lipoprotein
HOMA-Bhomeostatic model assessment index of beta-cell 
function
HOMA-IRhomeostatic model assessment index of insulin 
resistance
IB Investigator’s BrochureICH International Conference on HarmonisationICMJE International Committee of Medical Journal EditorsIEC independent ethics committeeIMP investigational medicinal productIRB institutional review boardIWRS interactive web response systemLDL low density lipoproteinLLoQ lower limit of quantification LSFV last subject first visitLSLV last subject last visitMAR missing at randomMedDRA Medical Dictionary for Regulatory ActivitiesMEN 2 Multiple Endocrine Neoplasia Type 2MI myocardial infarctionCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36005]
NYHA [LOCATION_001] Heart AssociationOAD oral antidiabetic drugPG plasma glucosePK pharmacokineticsPP per protocolPRO patient reported outcomeSAE serious adverse eventSAP statistical analysis plans.c. subcutaneous(ly)SGLT-[ADDRESS_36006] characteristicsSNAC sodium N-[8-(2-hydroxybenzoyl) amino] caprylateSTEMI ST-elevation acute myocardial infarctionS[LOCATION_003]R suspected unexpected serious adverse reactionT2DM type 2 diabetes mellitusTEAE treatment-emergent adverse eventsTIA transient ischaemic attackTMM Trial Materials ManualUNL Upper Normal LimitUTN Universal Trial NumberVLDL very low density lipoproteinCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 11 of 132
1 Summary
Objective(s) and endpoint(s):
Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on body weight in subjects with T2DM.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 1.8 
mg liraglutide subcutaneous and versus placebo, all in combination with metformin with or without 
a SGLT-2 inhibitor, in subjects with T2DM.
Primary endpoint
Change from baseline to week 26 in HbA 1c
Key secondary endpoints
Change from baseline to week 52 in HbA 1c
Change from baseline to week 26 and week 52 in:
!Body weight (kg)
!Fasting plasma glucose
If a subject after week 26 and week 52 achieves (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) American Diabetes Association target
Number of treatment-emergent adverse events during exposure to trial product, assessed up to 
approximately [ADDRESS_36007], assessed up to approximately 57 weeks.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 12 of 132
Trial design:
This is a 52-week, randomised, double-blind, double-dummy, active- and placebo-controlled, 
parallel-group, multicentre, multinational trial with 3 arms comparing the efficacy and safety of 
once-daily dosing of oral semaglutide vs. liraglutide and vs. placebo in subjects with T2DM.
Subjects will be randomised in a 2:2:1 manner to receive one of the following treatments:
!14 mg oral semaglutide once-daily
!1.8 mg liraglutide subcutaneous (s.c.) injection once-daily
!placebo once-daily 
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks. 
Trial population:
Number of subjects planned to be randomised: 690
Inclusion criteria:
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA 1cof 7.0–9.5 % (53–80.3 mmol/mol) (both inclusive).
5. Stable daily dose of metformin ( ≥[ADDRESS_36008]) alone or in combination with a stable daily dose of a SGLT-[ADDRESS_36009] 90 days prior to day of screening (fixed-dose combinations are allowed).
Key exclusion criteria:
1. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by [CONTACT_17993]). 
For certain specific countries: Additional specific requirements apply
2. Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.
3. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
4. History of pancreatitis (acute or chronic).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36010] (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric 
by[CONTACT_4897]).
6. Any of the following: myocardial infarction (MI), stroke or hospi[INVESTIGATOR_36175] 180 days prior to the day of screening. 
7. Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV.
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening.
9. Subjects with ALT > 2.5 × upper normal limit (UNL).
10. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 
mL/min/1.73 m2 as per Chronic Kidney Disease Epi[INVESTIGATOR_36176] 
(CKD-EPI).
11. Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria in a period of 90 days before the day of screening. An exception is 
short-term insulin treatment for acute illness for a total of ≤[ADDRESS_36011] 5 years (except basal and 
squamous cell skin cancer and carcinoma in situ ).
14. History of diabetic ketoacidosis.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 14 of 132
Key assessments:
Efficacy
!HbA 1c
!FPG
!Body weight
Safety
!Adverse events
!Hypoglycaemic epi[INVESTIGATOR_36177]:
Investigational medicinal products:
Test products:
!Semaglutide 3 mg, 7 mg and 14 mg, tablets
!Semaglutide placebo, 0 mg, tablets
Reference therapi[INVESTIGATOR_014]:
!Liraglutide, 0.6 mg (0.1 mL), 1.2 mg (0.2 mL), 1.8 mg (0.3 mL), solution for injections 
(strength: 6.0 mg/mL, pen-injector) 
!Liraglutide placebo, 0.1 mL, 0.2 mL, 0.3 mL, solution for injections (strength: 0.0 mg/mL, pen-
injector)
The subject’s de facto cost of SGLT-2 inhibitor and metformin (mono- or fixed-dose combination 
products) will be reimbursed in accordance with local legislation and Ethics Committee approval.CONFIDENTIAL
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36012] no.: 2015-005210-30 Version: 1.0 Page: 15 of 132
2 Flow chart
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36013] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_36014] RELATED
INFO/ASSESSMENTS
Informed consent x
In/exclusion criteria x x
Concomitant medication x x x x x x x x x x x x x x x x
Demography x
Tobacco use x
Concomitant illness and Medical x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36015] no.: 2015-005210-30 Version: 1.0 Page: 16 of 132
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36016] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
history
Diagnosis of diabetes/diabetes 
complicationsx
History of cardiovascular disease x
History of gallbladder disease x
History of gastrointestinal disease x
Randomisation x
Criteria for premature 
discontinuation of trial productx x x x x x x x x x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36017] no.: 2015-005210-30 Version: 1.0 Page: 17 of 132
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36018] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_36019] circumference x x x x x x
7-point profile x x x x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36020] no.: 2015-005210-30 Version: 1.0 Page: 18 of 132
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36021] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_36022] xex x x x x x x x x x x x x
Calcitonin x x x x x x x x
Biochemistry xfx x x x x x x x x x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36023] no.: 2015-005210-30 Version: 1.0 Page: 19 of 132
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36024] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
Haematology x x x x x x x x x x
Antibodies xgx x x x x x x x x
Adverse events xh   x x x x x x x x x x x x x x
Hypoglycaemic epi[INVESTIGATOR_1841] x x x x x x x x x x x x x x x
Technical complaints x x x x x x x x x x x x
TRIAL MATERIAL
IWRS call x x x x x x x x x x x x
Drug accountability x x x x x x x x x x x
Dispensing visit x x x x x x x x x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36025] no.: 2015-005210-30 Version: 1.0 Page: 20 of 132
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36026] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
REMINDERS
Dispense and/or collect diary x x x x x x x x x x x x x x
Attend visit fasting xix x x x x x x x
Handout and instruct in BG meter 
usex
Handout ID card x
Training in trial products, dosing 
instructions and pen handlingxjx x x x x x x x x x
Protocol UTN: U1111-1176-6029 Date: 02 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_36027] no.: 2015-005210-30 Version: 1.0 Page: [ADDRESS_36028] not exce ed 2 
weeks prior to randomisation (V2).
xbSubjects, who have discontinued trial product prematurely, are not required to attend V14 (Follow-up).
xcV13A and V14A are only applicable for subjects who have discontinued trial product prematurely
xd Dilated fundoscopy/fundus photography performed within [ADDRESS_36029] examination.
xe For women of child-bearing potential: Urine pregnancy test should also be performed at any time during the trial if a menstrual  period 
is missed, and/or according to local regulations/law.
xfAt V1, only ALT, creatinine and eGFR will be assessed as part of Biochemistry.
xg At randomisation, the antibody sampling must be done pre-dose. No antibody sampling should be done for visits occurring after V14 A 
(subjects who have discontinued trial product prematurely).
xh Adverse events reporting includes adverse events from the first trial-related activity after the subject has signed the informed  consent at
V1, however, pre-existing conditions identified as a result of the screening procedures should be reported as medical history.
xiFasting for blood sampling is defined as no food or liquid within the last [ADDRESS_36030] dispensing vi sit (V2) 
and at subsequent visits when judged necessary by [CONTACT_093]. The subjects must be trained in how to handle the injection  pen 
when handed out the first time and training must be repeated at regular intervals. The investigator must document that subjects  are 
instructed in the dosing requirements at every dispensing visit.
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 22 of 132
3 Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP)1and applicable regulatory requirements, and in 
accordance with the Declaration of Helsinki2.
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1 Background information
3.1.1 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a progressive, metabolic disease primarily characterised by 
[CONTACT_36269]. The pathogenesis is heterogeneous involving environmental, 
lifestyle and genetic factors leading to chronic hyperglycaemia caused by [CONTACT_36270], impaired insulin secretion due to abnormal beta-cell function and abnormal glucose 
metabolism in the liver3.
Optimal glycaemic control is the treatment goal in subjects with T2DM in order to prevent long-term complications associated with chronic hyperglycaemia
4. Despi[INVESTIGATOR_36178]-diabetic drugs, a significant proportion of subjects with T2DM do not achieve the recommended targets for glycaemic control
5,6.
3.1.2 Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone with a glucose-dependent stimulatory 
effect on insulin and inhibitory effect on glucagon secretion from the pancreatic islets7,8. Subjects 
with T2DM have a decreased incretin effect9-12. However, the insulinotropic action of GLP-[ADDRESS_36031] on gastric emptying; however this effect seems to diminish upon chronic exposure
14-16. These mechanisms of action make glucagon-like peptide-1 receptor agonists (GLP-1
RAs) an attractive pharmacological treatment for T2DM17-19.
3.1.3 Oral semaglutide  
Semaglutide is a long-acting GLP-1 RA structurally similar to liraglutide (Victoza®), a once-daily 
GLP-1 RA developed by [CONTACT_36271] T2DM. 
Compared to human native GLP-1, which has a short half-life, the semaglutide molecule has three 
minor but important modifications ensuring protraction of its action: amino acid substitutions at CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 23 of 132
position 8 (alanine to alpha-aminoisobutyric acid, a synthetic amino acid) and position 34 (lysine to 
arginine) and acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain to lysine 
in position 2620. The fatty di-acid side chain and the spacer mediate strong binding to albumin, 
thereby [CONTACT_36272]. The amino acid substitution at position 8 makes semaglutide less susceptible to degradation by [CONTACT_36273]-4 (DPP-4). The change in position [ADDRESS_36032] only one lysine in the sequence whereto a spacer can be 
attached.
Semaglutide is in development for oral once-daily treatment of T2DM. As the bioavailability of 
GLP-1 RAs is low when administered orally, semaglutide has been co-formulated with the 
absorption-enhancing excipi[INVESTIGATOR_36179] N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) to 
increase the bioavailability of semaglutide. The absorption-enhancing properties of SNAC co-
formulation are based on the  concept developed by 
[CONTACT_36274] a strictly time- and size-dependent manner, 
primarily via the transcellular route. The available data for semaglutide co-formulated with SNAC 
support that the absorption takes place in the stomach in a localised, buffered environment in close 
proximity to the tablet erosion. The absorption process is hampered if dosed with food, liquid or in 
the presence of significant stomach content. 
The absorption enhancement requires co-formulation between semaglutide and SNAC. Throughout 
this document “oral semaglutide” will refer to the drug product, that is, semaglutide co-formulated 
with 300 mg SNAC. 
3.1.4 Nonclinical data
[IP_ADDRESS] Semaglutide
The nonclinical programme for semaglutide was designed according to the ICH M3 guideline to 
support the clinical development
21. The standard nonclinical data package required to support phase 
[ADDRESS_36033] been completed. Semaglutide was generally well 
tolerated in animals (mice, rats and cynomolgus monkeys). Two potential safety issues have been 
identified and these are detailed below.
Thyroid C-cell tumours in rodents
Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were 
observed in 2-year carcinogenicity studies with semaglutide; thyroid hyperplasia was preceded by 
[CONTACT_36275]. C-cell changes have not been observed in long-term studies in non-
human primate. The observed pattern of effects in mice and rats and lack of these effects in the non-
human primate and in man suggest that the mechanism by [CONTACT_36276] C-
cells in rodents is the same as has been demonstrated for other GLP-1 RAs, including liraglutide. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 24 of 132
According to this mechanism, C-cell hyperplasia is mediated by [CONTACT_17978]-1 receptor and is not 
associated with RET (re-arranged during transfection) gene activation and rodents appear to be 
particularly sensitive, whereas humans are not. The relevance for human subjects is currently 
unknown, but considered to be low22.
Embryo−foetal development toxicity
Semaglutide caused embryo-foetal development toxicity in the rat through a GLP-[ADDRESS_36034] of semaglutide coincided with increased early foetal loss; however, there 
was no indication of a teratogenic potential of semaglutide in this species.
A review of the results from the nonclinical studies can be found in the investigator’s brochure (IB) 
for semaglutide (subcutaneous administration), edition 1023and the IB for oral administration of 
semaglutide (NN9924), edition 624, or any updates of these documents.
[IP_ADDRESS] SNAC
SNAC was developed as an absorption-enhancing excipi[INVESTIGATOR_36180]. The 
nonclinical programme to support clinical phase [ADDRESS_36035] 
been included at selected time points around peak concentrations of SNAC in two of the phase 3a 
trials in the PI[INVESTIGATOR_36181] (PI[INVESTIGATOR_15597] 1 and 2) with the intention to document that SNAC 
does not impair cellular respi[INVESTIGATOR_36182]. In addition, events of lactic acidosis must be 
reported as an AE requiring additional data collection, please refer to Section [IP_ADDRESS] , Section 12.1.5
and appendix B .   CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 25 of 132
The carcinogenicity studies demonstrated that SNAC was not carcinogenic to the transgenic rasH2 
mouse or the Sprague-Dawley rat. The doses tested covered total exposures of SNAC in plasma (in 
terms of AUC) of 2-fold in the mouse and up to 44-fold in the rat when compared to the mean total
exposure of SNAC in humans following a clinical dose of 300 mg SNAC/day.
A review of the SNAC results from the nonclinical studies can be found in the Investigator’s 
Brochure (IB) for oral administration of semaglutide (NN9924), edition 624, or any updates hereof.
3.1.5 Clinical data for oral semaglutide
A comprehensive clinical pharmacology programme including 12 trials has been completed, as well 
as a 26-week phase 2 dose-finding trial involving more than 600 subjects with T2DM.
For details on the individual trials, please see the IB for oral administration of semaglutide 
(NN9924) edition 624, or any updates hereof.
[IP_ADDRESS] Pharmacokinetics
In the multiple-dose trial (NN9924-3991), oral semaglutide has demonstrated a long mean terminal 
half-life (t ½) ranging from 153 to 161 hours (~1 week) and a median time to reach maximum 
observed concentration (t max) ranging from 1 to 2 hours in healthy subjects.
In multiple-dose pharmacokinetics (PK) trials, the exposure to oral semaglutide increased with 
increasing dose. Overall, the pharmacokinetic properties of semaglutide appeared similar in healthy 
subjects and in subjects with T2DM.
Exposure to semaglutide exhibits a substantially greater dose-to-dose variation following oral 
administration compared to subcutaneous (s.c.) administration. However, when administered orally 
once-daily the PK properties of semaglutide, i.e. low clearance and long half-life, will limit the 
variation in exposure at steady state.
Data obtained following investigation of different dosing conditions for oral semaglutide have 
demonstrated that subjects should take the oral semaglutide tablet in the morning in a fasting state 
and at least [ADDRESS_36036] meal of the day. 
 
 
 
 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 26 of 132
 
 
 
In subjects with mild to severe hepatic impairment, the exposure to semaglutide appeared to be 
unaffected by [CONTACT_36277], whereas the exposure to SNAC (in terms of both 
AUC and C max) was increased for subjects with hepatic impairment as compared to subjects with 
normal hepatic function.
All tablets of oral semaglutide contain 300 mg of SNAC regardless of the semaglutide dose. SNAC 
is rapi[INVESTIGATOR_19627] a median t maxranging from 0.35 −0.5 hours in healthy subjects and from 
0.52−1.43 hours in subjects with T2DM. It is extensively metabolised and no accumulation of 
SNAC has been observed in clinical trials.
[IP_ADDRESS] Efficacy
The efficacy of oral semaglutide in adult subjects with T2DM was investigated in a 26-week phase 
2 dose-finding trial (NN9924-3790). In this trial, placebo or one of the following doses of oral 
semaglutide were administered once daily: 2.5, 5, 10, 20 and 40 mg.
Results from the trial showed that oral semaglutide effectively lowered glycosylated haemoglobin 
(HbA 1c) and body weight. Placebo-adjusted reductions in HbA 1cwere dose-dependent and clinically 
relevant for all oral semaglutide treatment arms at week 26 (range: −0.40 % to −1.59 %). Placebo-
adjusted reductions in body weight were dose-dependent and statistically significant for oral 
semaglutide treatment doses of 10 mg and above at week 26 (range: −3.61 kg to −6.98 kg).
[IP_ADDRESS] Safety
In the clinical trials completed so far, no unexpected safety findings have been identified for oral 
semaglutide administered up to 40 mg once daily. Consistent with other GLP-1 RAs, commonly 
reported adverse events (AEs) included nausea and vomiting, most of which were mild to moderate 
in severity. In line with findings for other GLP-1 RAs, an increase in heart rate and serum levels of 
lipase and amylase has also been observed in subjects exposed to oral semaglutide.
In addition to the 13 completed clinical trials with oral semaglutide, SNAC has been investigated in 
the programme of orally administrated heparin in combination with SNAC (heparin/SNAC). The 
heparin/SNAC programme  included 29 phase 1 trials (SNAC doses 
ranged from 0.172–10.5 g). In three of these trials, SNAC alone was investigated (to a maximum 
dose of 10.5 g). The trials covered formulation development, food effect, hepatic and renal 
impairment, age effect and drug-drug interaction. The programme also included a total of three 
phase 2 and 3 trials in which the effects of orally delivered heparin solution (with >1.5 g SNAC CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 27 of 132
three times a day) was investigated. The overall safety profile of oral semaglutide and 
heparin/SNAC indicates that SNAC is safe and well-tolerated. 
For further details, please see the IB for oral administration of semaglutide (NN9924) edition 624, or 
any updates hereof.
3.1.6 Liraglutide
The selected active comparator in this trial is liraglutide, an injectable GLP-1 RA approved for 
once-daily administration. Liraglutide was developed by [CONTACT_36278] 2009 in the 
EU, in 2010 in Japan, and in 2010 in the US under the trade name [CONTACT_36373]® to improve glycaemic 
control in adults with T2DM.
For further details, please see the current approved label for Victoza®25,26.
For an assessment of benefits and risks of the trial, see Section 18.1.
3.2 Rationale for the trial
Many patients with T2DM are not in glycaemic control with the currently marketed oral anti-
diabetic drugs (OADs). Nevertheless, treatment with more efficacious injectable therapi[INVESTIGATOR_36183]-[ADDRESS_36037] GLP-1 RA in development in a tablet formulation and it has the potential of becoming a 
new attractive treatment option early in the treatment cascade due to its effects on both 
hyperglycaemia and body weight. 
The purpose of the present trial is to compare oral semaglutide with liraglutide, a well-established, 
injectable GLP-1 RA, in terms of glycaemic control, weight loss and other efficacy and safety 
parameters in subjects with T2DM inadequately controlled on metformin only or metformin in 
combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor or a fixed-dose
combination of metformin and SGLT-2 inhibitor.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36038] of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide 
subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2
inhibitor, on glycaemic control in subjects with type 2 diabetes mellitus (T2DM).
4.1.[ADDRESS_36039] after completion of the trial. 
4.2.1 Primary endpoint
Change from baseline to week 26 in HbA 1c
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) 
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
Change from baseline to week 52 in: 
!HbA 1c*
!Body weight (kg)*CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 29 of 132
Change from baseline to week 26 and week 52 in:
!Fasting plasma glucose (FPG)*
!7-point self-measured plasma glucose (SMPG) profile
– Mean 7-point profile
– Mean postprandial increment (during all meals)
!Body weight (%)
!Body mass index (BMI)
!Waist circumference
!Fasting lipid profile (total cholesterol, low density lipoprotein [LDL] cholesterol, very low 
density lipoprotein [VLDL] cholesterol, high density lipoprotein [HDL] cholesterol, 
triglycerides, free fatty acids)
!Patient reported outcomes 
– Diabetes Treatment Satisfaction Questionnaire (DTSQs)
If a subject after week 26 and week 52 achieves (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) American Diabetes Association (ADA) target*
!HbA 1c≤6.5 % (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) 
target
!HbA 1creduction ≥1 % (10.9 mmol/mol)
!Weight loss ≥3%  
!Weight loss ≥5%  
!Weight loss ≥10 % 
!HbA 1c< 7.0 % (53 mmol/mol) without  hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglyceamia) and no weight gain
!HbA 1creduction ≥1 % (10.9 mmol/mol) and weight loss ≥3%
Time to event
!Time to rescue medicationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 30 of 132
Supportive secondary safety endpoints
!Number of treatment-emergent adverse events (TEAEs) during exposure to trial product, 
assessed up to approximately 57 weeks*
!Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_36184], assessed up to approximately 57 weeks*
!Treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36185], assessed up to approximately 57 weeks (yes/no)
Change from baseline to week 26 and week 52 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination (week 52 only)
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross-reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross-reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeks:
!Anti-semaglutide binding antibody levels
* Key supportive secondary endpoints prospectively selected for disclosure (e.g. clinicaltrials.gov 
and EudraCT)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 31 of 132
5 Trial design
5.1 Type of trial
This is a 52-week, randomised, double-blind, double-dummy, active- and placebo-controlled, 
parallel-group, multicentre, multinational trial with 3 arms comparing the efficacy and safety of 
once-daily dosing of oral semaglutide vs. liraglutide and vs. placebo in subjects with T2DM.
Subjects will be randomised in a 2:2:1 manner to receive one of the following treatments:
!14 mg oral semaglutide once-daily
!1.8 mg liraglutide subcutaneous (s.c.) injection once-daily
!placebo once-daily 
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks. 
A schematic diagram of the trial design is shown in Figure 5–1 .
Figure 5–[ADDRESS_36040] of oral 
semaglutide compared to placebo. Subjects will be randomised between the three treatment arms 
and the trial will be double-blinded to minimise bias. The randomisation will be stratified based on 
anti-diabetic background medication at screening (metformin only/metformin in combination with a 
SGLT-2 inhibitor) and descent (Japanese subjects/non-Japanese subjects) to ensure a 2:2:1 
distribution of the three treatment arms within each stratum .The aim is to randomise a minimum of 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 32 of 132
125 subjects on a background medication including a SGLT-2 inhibitor, and a minimum of 75 
Japanese subjects out of the planned total number of subjects (690).
Semaglutide will be administered orally and liraglutide as s.c. injections. To maintain the blinding 
of the trial, a double dummy design will be applied. Accordingly, all subjects randomised to oral 
semaglutide will also receive liraglutide placebo injections, subjects randomised to liraglutide will 
also receive semaglutide placebo tablets and subjects randomised to placebo will receive both 
semaglutide placebo tablets and liraglutide placebo injections. 
There will be strict glycaemic rescue criteria in place to ensure acceptable glycaemic control during 
the trial for all treatment arms, including the placebo arm. 
The treatment duration will be [ADDRESS_36041] of oral semaglutide on HbA1c and body weight that 
is considered adequate and meaningful. There will not be an interim analysis at week 26. The 
subjects will sign up for 52 weeks when they sign the informed consent.
The follow-up period is 5 weeks to allow for wash-out of semaglutide and to prevent interference in 
the antibody assay.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 33 of 132
5.3 Treatment of subjects
Treatment of subjects is summarised in Table 5–1 .
Oral semaglutide treatment
Oral semaglutide is a long-acting GLP-1 RA to be administered orally once-daily. Subjects 
randomised to oral semaglutide will initiate treatment with 3 mg oral semaglutide once-daily and 
follow a fixed 4-week dose escalation regimen until reaching the maximum maintenance dose of 14 
mg oral semaglutide once-daily, as illustrated in Table 5–[ADDRESS_36042] (P3) (see Section 2), the investigator should follow-up on compliance 
and potential technical issues regarding the dose escalation that was done by [CONTACT_36279]. At P3, the subject will be instructed to dose escalate to 1.[ADDRESS_36043] not be changed during the 
course of the trial once the 1.8 mg maintenance dose of liraglutide has been reached.
Placebo treatment
Treatment with semaglutide placebo tablets and liraglutide placebo injections will follow the same 
rules as outlined for the respective active treatments above. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 34 of 132
Table 5–[ADDRESS_36044] visit in each period V1 V2 V4 V6 V14
Duration of each period 2 weeks 4 weeks 4 weeks 44 weeks 5 weeks
Treatment arm N
Oral semaglutide 276 Screening3 mg oral 
semaglutide
tablet
+ liraglutide 
placebo 
injection 0.1 mL
with weekly 
volume-
matched 
escalation to 0.2 
mL and 0.3 mL7 mg oral 
semaglutide 
tablet
+ liraglutide 
placebo 
injection 0.3 mL14 mg oral 
semaglutide
tablet
+ liraglutide 
placebo 
injection 0.3 mLFollow-up
Liraglutide 276 Screening0.6 mg (0.1 mL) 
liraglutide  
injection (with 
weekly 
escalation
to 1.2 mg (0.2 
mL) and
1.8 mg (0.3 mL)
+ semaglutide 
placebo 
matching tablet 1.8 mg (0.3 mL) 
liraglutide  
injection 
+ 7 mg oral 
semaglutide 
placebo 
matching tablet 1.8 mg (0.3 mL) 
liraglutide   
injection
+ 14 mg oral 
semaglutide 
placebo 
matching tabletFollow-up
Placebo138 Screening3 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.1 mL
with weekly 
volume-
matched 
escalation to 0.2 
mL and 0.3 mL7 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.3 mL 14 mg oral
semaglutide 
placebo 
matching tablet
+ liraglutide 
placebo 
injection 0.3 mLFollow-upCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 35 of 132
The following trial products will be supplied by [CONTACT_3454] A/S, Denmark: 
!Semaglutide 3 mg, 7 mg and 14 mg, tablets
!Semaglutide placebo, 0 mg, tablets
!Liraglutide, 0.6 mg (0.1 mL), 1.2 mg (0.2 mL), 1.8 mg (0.3 mL), solution for injections 
(strength: 6.0 mg/mL, pen-injector) 
!Liraglutide placebo, 0.1 mL, 0.2 mL, 0.3 mL, solution for injections (strength: 0.0 mg/mL, pen-
injector)
5.3.1 Dosing instructions
Oral semaglutide/semaglutide placebo
Absorption of oral semaglutide is significantly affected by [CONTACT_36280], hence 
dosing should be once-daily in the morning in a fasting state and at least [ADDRESS_36045] 
meal of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/4 
fluid oz). The tablets must be swallowed whole by [CONTACT_36281]. 
(Table 9–2 ). Furthermore, other oral medication can be taken [ADDRESS_36046].
Liraglutide/liraglutide placebo
Liraglutide/liraglutide placebo should be administered once-daily as subcutaneous injection (under 
the skin) in the abdomen, thigh or upper arm. It is given independent of meals and preferably at the 
same time each day.
5.3.[ADDRESS_36047] continue their anti-diabetic background 
medication (metformin or metformin+SGLT-2 inhibitor) throughout the entire trial. The 
background medication must be maintained at the same dose level as given at trial entrance and 
with the same frequency during the entire treatment period unless rescue medication is needed or a 
safety concern related to the background medication arises.
In addition, all background medication:
!is considered to be non-investigational medicinal product (NIMP)
!will not be provided by [CONTACT_3454] A/S, except if required by [CONTACT_427]
!should be used in accordance with standard of care and current approved label in the individual 
country 
!should not exceed the maximum approved dose in the individual country
5.[ADDRESS_36048]
When discontinuing trial products, either at the scheduled end of treatment visit (see Section 8.1.5 ) 
or if trial product is discontinued prematurely (see Section 8.1.6 ), the subject should be switched to CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36049] 
date on trial products (to avoid interference with the antibody assay for oral semaglutide).
Throughout the protocol, last date on trial product is defined as date of the subject’s last dosage of 
trial product.
As this trial is a phase 3a trial, oral semaglutide will not be available for prescription until after 
marketing authorisation.
5.5 Rationale for treatment
For oral semaglutide, the three dose levels (3, 7 and 14 mg), treatment initiation with the lowest 
dose and the 4-week dose escalation steps have been chosen based on data from the phase [ADDRESS_36050] sufficient data on efficacy 
and safety in accordance with the trial objectives.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 37 of 132
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened: 1150
Number of subjects planned to be randomised: 690
For Japan only: Approximately 75 subjects planned to be randomised/started on trial product(s).
Number of subjects expected to complete the trial on or off trial product: [ADDRESS_36051] be answered “yes”.
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA 1cof 7.0–9.5 % (53-80.3 mmol/mol) (both inclusive).
5. Stable daily dose of metformin ( ≥[ADDRESS_36052]) alone or in combination with a stable daily dose of a SGLT-2 inhibitor 
(all doses approved as maintenance therapy) ≥[ADDRESS_36053] be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by [CONTACT_17993]).
For [LOCATION_013] only: Only highly effective methods of birth control are accepted (i.e. one that 
results in less than 1% per year failure rate when used consistently and correctly such as 
implants, injectables, combined oral contraceptives, some intrauterine device), or sexual 
abstinence or vasectomised partner.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
4. Receipt of any investigational medicinal product within 90 days before screening.
5. Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.
6. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 38 of 132
7. History of pancreatitis (acute or chronic).
8. History of major surgical procedures involving the stomach and potentially affecting absorption 
of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric by[CONTACT_4897]).
9. Any of the following: myocardial infarction (MI), stroke or hospi[INVESTIGATOR_36186] 180 days prior to the day of screening. 
10. Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV.
11. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
12. Subjects with ALT > 2.5 × upper normal limit (UNL).
13. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 
m2 as per Chronic Kidney Disease Epi[INVESTIGATOR_36176] (CKD-EPI).
14. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 days before the day of screening. An exception is short-term 
insulin treatment for acute illness for a total of ≤[ADDRESS_36054] 5 years (except basal and squamous 
cell skin cancer and carcinoma in situ ).
17. History of diabetic ketoacidosis.
6.[ADDRESS_36055] of treatment on glycaemic parameters, rescue criteria will be applied at week 8 and onwards. 
If any of the FPG values (including fasting SMPG) exceed the limits outlined below and no 
intercurrent cause of the hyperglycaemia can be identified, a confirmatory FPG (at central 
laboratory) should be obtained by [CONTACT_36282] a re-test. If the confirmatory FPG also 
exceeds the value described below, the subject should be offered rescue medication (i.e. 
intensification of anti-diabetic background medication and/or initiation of new anti-diabetic medication):
!13.3 mmol/L (240 mg/dL) from week 8 to end of week 13
!11.1 mmol/L (200 mg/dL) from week [ADDRESS_36056] should be offered rescue medication if:
!HbA
1c(at central laboratory) >8.5 % (69.4 mmol/mol) from week 26 to end of treatment.
It is important for trial integrity that only subjects actually needing treatment intensification (as 
defined above) are started on rescue medication. Subjects that are started on rescue medication should continue to follow the protocol-specified visit schedule. Rescue medication should be CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 39 of 132
prescribed at the investigator’s discretion as add-on to randomised treatment and according to 
ADA/European Association for the Study of Diabetes guidelines27and28(excluding GLP-1 RAs,
DPP-4 inhibitors and amylin analogues). Rescue medication and any changes hereto should be captured on the concomitant medication form in the electronic case report form (eCRF), see Section 8.2.[ADDRESS_36057], if the following applies:
1. Safety concern related to trial product or unacceptable intolerability
2. Inclusion in the trial in violation of the inclusion and/or exclusion criteria
3. Pregnancy
4. Intention of becoming pregnant
5. Simultaneous participation in another clinical trial of an approved or non-approved  
investigational medicinal product (IMP)
6. Calcitonin ≥ 100 ng/L
If a criterion for premature discontinuation of trial product is met, trial product should not be re-
initiated but subjects should continue with the scheduled site contacts.
See Section 8.1.[ADDRESS_36058]’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial.
See Section 8.1.[ADDRESS_36059] data
interpretation. The HbA 1climits 7.0–9.5 % (53–80.3 mmol/mol) have been chosen to include CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36060] abnormalities (ALT > 2.5 × UNL) will be 
excluded to avoid potential confounding of liver safety assessments. In addition, subjects with 
moderate, severe or end-stage renal impairment will be excluded due to restrictions in the labels of 
the allowed background medication. As SGLT-[ADDRESS_36061] trial population 
resembling the target population in common practice. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36062] Visit (FSFV) – Last Subject First Visit (LSFV): 26 weeks
Planned FSFV: 10-Aug-2016Planned Last Subject Last Visit (LSLV): 03-Apr-2018End of trial is defined as LSLV.
Recruitment:
The screening and randomisation rate will be followed closely via the IWRS in order to estimate 
when to stop screening. All investigators will be notified immediately when the recruitment period 
ends, after which no further subjects may be screened and the IWRS will be closed for further 
screening.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov, novonordisk-trials.com and the 
Clinical Trials Information Japi[INVESTIGATOR_36187].jp. According to the Novo Nordisk Code of 
Conduct for Clinical Trial Disclosure29, it will also be disclosed according to other applicable 
requirements such as those of the International Committee of Medical Journal Editors (ICMJE)30,
the U.S. Food and Drug Administration Amendment Act (FDAAA)31, European Commission 
Requirements32,33and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk A/S may 
disclose the investigator’s contact [CONTACT_18026]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 42 of 132
8 Methods and assessments
8.1 Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial related activity, see 
Section 18.1.2 .
Refer to flowchart (Section 2) for number and timing of visits and specific assessments to be 
performed. 
Each subject will attend [ADDRESS_36063] (within the visit window) and entered into the eCRF. Subjects will 
be invited for the next scheduled visit according to the visit schedule.
The investigator must keep a log of staff and a delegation of task(s) list at site. Investigator must 
sign the log of staff and the delegation of task(s) at site prior to the delegation of tasks.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log. 
8.1.[ADDRESS_36064] address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
A screening session must be made in the IWRS. Each subject will be assigned a unique 6-digit 
subject number which will remain the same throughout the trial.
Once all data relating to V1 have been obtained, these must be reviewed, dated and signed by [CONTACT_36284]/or documented in medical records to assess that the subject is eligible to continue 
in the trial.
Screening failures: For screening failures the screening failure form in the eCRF must be 
completed with the reason for not continuing in the trial. Serious adverse events (SAEs) from CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36065] has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the subject has failed one of the inclusion or exclusion criteria related to 
laboratory parameters. However, in case laboratory samples are lost (e.g. haemolysed/displaced), 
re-sampling is allowed.
8.1.[ADDRESS_36066] attend several visits in a fasting state (see Section 2).
Fasting for blood sampling is defined as no food or liquid within the last [ADDRESS_36067] be taken after blood sampling (see Section 5.3.1 for dosing instructions). Other 
oral medication can be taken [ADDRESS_36068] the fasting blood samples done within the visit window for the relevant visit.
Fasting samples:
!fasting plasma glucose (FPG)
!fasting lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, very low 
density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, free fatty acids)
8.1.[ADDRESS_36069] be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All V2 assessments must be performed before administration of first dose of trial product.
Trial products (see Section 9) will be dispensed to the subject by [CONTACT_779], hospi[INVESTIGATOR_36188]-of-
treatment visit (see Section 2). The investigator must document that subjects are trained in the 
dosing instructions at every dispensing visit, please see Section 5.3.[ADDRESS_36070] will be captured in the eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 44 of 132
8.1.4 Phone contacts
The phone contacts should be conducted as outlined in the flowchart (see Section 2).
At V2, the investigator should instruct the subject to dose escalate liraglutide/liraglutide placebo to 
1.[ADDRESS_36071] (P3), the 
investigator should follow-up on compliance and potential technical issues regarding the dose 
escalation that was done by [CONTACT_36285]. At P3, the subject will be 
instructed to dose escalate to 1.8 mg once-daily.
8.1.5 End-of-treatment (visit 13) and Follow-up (visit 14)
Subjects, who stay on trial product throughout the trial, must attend the End-of-treatment visit 
(V13) 52 weeks after randomisation and the Follow-up visit (V14) [ADDRESS_36072] (+3 days visit window). A completion call must be performed in the IWRS after 
completion of V13 (see Section 10).
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled V14, the site 
should consult the contacts provided by [CONTACT_423] (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow up and this should 
be specified in the end-of-trial form.
8.1.[ADDRESS_36073] and Follow-up (visits 13A and 14A)
Subjects who discontinue trial product prematurely should attend V13A scheduled to take place on 
the day of discontinuation of trial product (+ 3 days visit window). V14A should be scheduled 5 
weeks (+3 days visit window) after the last date on trial product. The primary reason for premature 
discontinuation of trial product must be specified in the end-of-trial form in the eCRF, and final 
drug accountability must be made. A treatment discontinuation session must be performed in the 
IWRS at V13A (see Section 10).
If premature discontinuation of trial product is decided during a scheduled visit, the visit will be 
converted into a V13A and trial procedures must be performed accordingly.
Subjects should continue with the originally scheduled site contacts after V13A and up to and 
including V13. If necessary, in order to retain the subject in the trial, site visits can be replaced by [CONTACT_36287] V14A. However, if a subject is unable or unwilling to attend all subsequent 
visit(s), the investigator should at least aim to have the subject attend V9 (week 26) and the End-of-
treatment visit (V13) as these visits should be performed for all subjects, if at all possible (except 
subjects who withdraw informed consent, see Section 8.1.7 ). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36074] cannot be reached (by [CONTACT_36288]) at the scheduled V12, the site should consult the contacts provided by [CONTACT_423] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow-up and this should be specified in the end of trial form. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact [CONTACT_36289] (for withdrawal procedures see Section 8.1.7 ).  
8.1.[ADDRESS_36075] aim to undertake procedures 
for V13A as soon as possible and V14A should be scheduled 5 weeks (+3 days visit window) after 
the last date on trial product, if the subject agrees to it.
The end-of-trial form must be completed and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS (see Section 10). The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.
8.1.8 Investigator assessments
Review of diaries, Patient Reported Outcomes (PROs), laboratory reports, ECGs and 
fundoscopy/fundus photography must be documented either on the documents or in the subject’s 
medical record.
If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
The documents must be retained at the site as source documentation.
For ECGs, physical examinations and eye examinations, the evaluations must follow the categories:
!Normal
!Abnormal
– Was the result clinically significant? (yes/no)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 46 of 132
The evaluation should be based on investigator’s judgement.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is clinically significant or not clinically significant. All laboratory printouts must be signed 
and dated by [CONTACT_36290]. The signed laboratory report is retained at 
the site as source documentation.
In case of abnormal clinically significant findings found as a result of screening procedures 
conducted at V1 or assessments revealing baseline conditions at V2, the investigator must state a 
comment in the subject’s medical record and record this in the medical history/concomitant illness 
form in the eCRF. 
The Investigator or his/her delegate must collect and review the PROs and diaries for completeness 
and to ensure that AEs are reported. 
8.[ADDRESS_36076] related information/assessments
8.2.1 Demography
Demography will be recorded in the eCRF at screening and consists of:
!Date of birth (according to local regulation)
!Sex
!Ethnicity (according to local regulation)
!Race (according to local regulation)
8.2.2 Diabetes history and diabetes complications
Diabetes history and diabetes complications will be recorded on a disease specific form at screening 
and consists of:
!Date of diagnosis of type 2 diabetes
!Information regarding diabetes complications including date of onset
oDiabetic retinopathy
oDiabetic neuropathy
oDiabetic nephropathy
Please note that macroangiopathy (including peripheral arterial disease) should be reported on the
disease specific form History of cardiovascular disease (see Section 8.2.3 ).
8.2.3 Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (V1) or found as a result 
of a screening procedure or other trial procedures performed before exposure to trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36077] be recorded in the eCRF on the disease specific forms only, i.e. not on the 
medical history/concomitant illness form:
!History of cardiovascular disease (CVD) (e.g. ischaemic heart disease, MI, heart failure incl. 
NYHA class, hypertension, stroke, peripheral arterial disease)
!History of gallbladder disease (e.g. gallstone, cholecystitis, cholecystectomy)
!History of gastrointestinal disease (e.g. gastroesophageal reflux disease, ulcer disease, chronic 
gastritis)
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE (see Section 12).
It must be possible to verify the subject’s medical history in source documents such as subject’s 
medical record. If a subject is not from the investigators own practice, the investigator must make 
reasonable effort to obtain a copy of subject’s medical record from relevant party, e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
[CONTACT_18031](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.[ADDRESS_36078] be recorded at each visit as they occur. 
The information collected for each concomitant medication includes
!trade name [CONTACT_18058]
!indication
!start date and stop date or continuation
!only applicable for anti-diabetic medication: start date of current dose and total daily dose
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36079] be performed on female subjects of childbearing potential as described in 
Section 8.4.7 (pregnancy testing). Female subjects of childbearing potential must be instructed to 
use an adequate contraceptive method throughout the trial and until 5 weeks after end of treatment.
For [LOCATION_013] only: Only highly effective methods of birth control are accepted (i.e. one that results 
in less than 1% per year failure rate when used consistently and correctly such as implants, 
injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or 
vasectomised partner.
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
Female of non-childbearing potential is defined as:
!Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal ligation 
!Postmenopausal defined as no menses for 12 months without an alternative medical cause
!Other medical reasons preventing childbearing potential
8.2.[ADDRESS_36080] one cigarette 
or equivalent daily.
Smoking status:
!Never smoked
!Previous smoker, smoking stop date
!Current smoker
8.3 Efficacy assessments
8.3.1 Laboratory assessments for efficacy
For overall laboratory process see Section 8.5. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 49 of 132
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following efficacy laboratory parameters (for fasting 
see Section 8.1.2 ):
Glucose metabolism:
!HbA 1c
!FPG (see Section [IP_ADDRESS] )
Fasting lipid profile: 
!Total cholesterol
!LDL cholesterol
!HDL cholesterol
!Triglycerides
!VLDL cholesterol
!Free fatty acids
[IP_ADDRESS] Fasting plasma glucose 
FPG is measured at the central laboratory in order to evaluate glycaemic control. The subject must 
attend these visits fasting (see Section 8.1.2 ).
A central FPG result ≤3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be 
reported as a hypogly caemic epi[INVESTIGATOR_36189] a clinical laboratory adverse event (CLAE) at the 
discretion of the investigator (see Section 12.1.1 ).
8.3.2 Self-measured plasma glucose
At V1, subjects will be provided with a blood glucose meter (BG meter) including auxiliaries as 
well as instructions for use. The subjects will be instructed in how to use the device, and the 
instruction will be repeated as necessary duri ng the trial. In case a hypoglycaemic epi[INVESTIGATOR_36190], the provided BG meter should be used for SMPG measurement.
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capi[INVESTIGATOR_36191], which will be 
shown on the display. Only the BG meters provided by [CONTACT_3454] A/S should be used for the 
measurements required in the protocol.
Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be 
transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy 
is later detected, between the diary and the SMPG data obtained at the phone contact, the values in 
the eCRF must be corrected.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36081] will be instructed to perform a 7-point SMPG profile three times during the trial period 
(see Section 2) using the BG meter provided for the trial. The 7-point SMPG profile should be 
performed on a day where the subject does not anticipate unusual strenuous exercise. The 7-point 
SMPG profile should preferably be taken within a week prior to the visit.
The record of each SMPG measurement should include the following seven time points:
!before breakfast
![ADDRESS_36082]
!before lunch
!90 minutes after start of lunch
!before dinner
!90 minutes after start of dinner
!at bedtime
8.3.[ADDRESS_36083] be measured and recorded in the eCRF in kilogram or pound (kg or lb), with one 
decimal (with an empty bladder, without shoes and only wearing light clothing). The body weight 
should be assessed on the same calibrated weighing scale equipment throughout the trial, if 
possible.
Height is measured without shoes in centimetres or inches and recorded in the eCRF to nearest ½ 
cm or ¼ inch.
8.3.[ADDRESS_36084] accessible. The tape should touch the skin but not compress soft tissue and CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36085] is breathing out gently.
8.3.5 Patient reported outcomes questionnaires
PRO will be assessed using the questionnaire:
Diabetes Treatment Satisfaction Questionnaire (DTSQ)[ADDRESS_36086]’s treatment satisfaction. This questionnaire 
contains 8 items that measures the treatment satisfaction for subjects’ diabetes treatment in terms of 
convenience, flexibility and general feelings regarding treatment.
8.4 Safety assessments
8.4.1 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12and appendix B .
[IP_ADDRESS] Medication error 
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form (see Section [IP_ADDRESS] , 
12.1.5 and appendix B ): 
!Trial product(s) involved 
!Classification of medication error
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4 and appendix B .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 52 of 132
[IP_ADDRESS] Adverse events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event defined as:
– ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
– ALT or AST > 3x UNL and total bilirubin > 2x UNL *
– Hepatic event leading to trial product discontinuation.
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
See Section 12and appendix B for details about the additional information to report.
Note that additional assessments will be required according to appendix B in case of: 
!suspi[INVESTIGATOR_36194]
!suspi[INVESTIGATOR_36195]
!increased levels of creatine kinase
!increased levels of aminotransferase
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 53 of 132
8.4.2 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
Section 2and 8.1.8 ). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
8.4.[ADDRESS_36087] be recorded in the eCRF. The actual value of the blood pressure measurement should be 
recorded in the eCRF (without rounding). The same equipment should be used throughout the trial.
Pulse
Pulse (beats per minute) must be recorded in the eCRF at site visits after resting for 5 minutes in a 
sitting position.
8.4.4 Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by [CONTACT_36292]. Results of the dilated fundoscopy/fundus photography 
will be interpreted by [CONTACT_093] (see Section 8.1.8 ).
If dilated fundoscopy/fundus photography has been performed within [ADDRESS_36088] be available prior to randomisation.
If the dilated fundoscopy/fundus photography is performed before the subject has signed the 
informed consent form, it must be documented in the medical records that the reason for performing 
the procedure was not related to this trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 54 of 132
8.4.5 Electrocardiogram (12-lead)
12-lead ECG will be performed as per flowchart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.[ADDRESS_36089]-baseline ECG is suggestive of new MI, the investigator will 
be notified and a confirmatory ECG should be performed. Unless already done, the investigator 
should report this as an AE or a SAE at investigator’s discretion and according to Section 12.1. 
Additional ECG recordings can be performed at the investigator’s site at investigator’s discretion at 
other visits than the planned ECG visits. All these ECGs will undergo central assessment. The 
reason for additional ECG assessments should be documented and an AE should be reported if 
applicable.
All findings suggestive of new MI detected by [CONTACT_36293] (EAC) (see Section 12.7.2 ).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 55 of 132
8.4.6 Laboratory assessments for safety
For overall laboratory process see Section 8.5.
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following safety laboratory parameters:
Haematology:
!Haemoglobin
!Haematocrit
!Leucocytes
!Thrombocytes
!Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
Biochemistry: 
!Alanine aminotransferase (ALT)
!Albumin
!Alkaline phosphatase (ALP)
!Amylase
!Aspartate aminotransferase (AST)
!Bilirubin, total
!Calcium, total
!Creatinine 
!eGFR per CKD-EPI36
!Creatine kinase (CK)
!Lipase
!Potassium
!Sodium
!Urea
Hormones:
!Calcitonin
Other parameters:
!Antibodies (see Section 8.4.8 )
In case any calcitonin value at any time during the trial is ≥ 10 ng/L, the algorithm in appendix A
must be followed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36090] semaglutide at selected visits 
(see Section 2). Positive anti-semaglutide binding antibody samples will be further characterised for 
cross reactivity to native GLP-1. Samples which are positive for anti-semaglutide binding 
antibodies will be further characterised for in vitro neutralising effect towards semaglutide. In 
addition, samples which are positive for antibodies cross-reacting with native GLP-[ADDRESS_36091] be done pre-dose. 
Antibody samples will be stored as described in Section 24.2.
8.4.9 Hypoglycaemic epi[INVESTIGATOR_36196] (PG) should always be measured and recorded when a hypoglycaemic epi[INVESTIGATOR_36190]. 
All PG values:
!≤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the diary according to the instructions below throughout the trial from V1 to 
end of trial.
Upon onset of a hypoglycaemic epi[INVESTIGATOR_1865], the subject is recommended to measure plasma glucose 
every 15 minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been 
resolved in accordance to current guidelines37.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 57 of 132
A SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms  must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms will per default be considered as  one hypoglycaemic epis ode until a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
epi[INVESTIGATOR_36198]/or symptoms.
In case of several low SMPG values within the hypoglycaemic epi[INVESTIGATOR_1865], the lowest value is the one 
that will be reported as the SMPG value for th e hypoglycaemic epi[INVESTIGATOR_36199]/or symptom.
The record should include the following information: 
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865].
!Stop date and time of the hypoglycaemic epi[INVESTIGATOR_1865] (stop time is the first time the PG value is > 
3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved).
If a stop date and time is not reported, a h ypoglycaemic epi[INVESTIGATOR_36200] a period of 60 
minutes.
!The PG level before treating the epi[INVESTIGATOR_1865] (if available) and any follow up measurements. 
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_36201], the remaining values will be kept as source data in the diary.
!Whether the epi[INVESTIGATOR_36202] (Yes/No).
A hypoglycaemic epi[INVESTIGATOR_36203]. 
!Whether the subject was able to treat him/herself.
If the severity of a hypoglycaemic epi[INVESTIGATOR_1865] a ggravates, only one hypoglycaemic epi[INVESTIGATOR_36204].
!Date and time of last oral trial product administration, and for pen-injection and selected anti-
diabetic medications administered prior to the epi[INVESTIGATOR_1865], date and time as well as dose must be 
collected.
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865].
!Whether the epi[INVESTIGATOR_36205].
!Change in any concomitant illness.
!Any sign of fever and/or other acute disease.
!Whether the subject was asleep when the epi[INVESTIGATOR_36206].
– If yes, whether the symptoms of the epi[INVESTIGATOR_36207].
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration37.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36092] is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-medical 
person)?
!Where the treatment was administered (in clinic/emergency room/ hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an ambulance or not)
!Type of treatment provided by [CONTACT_19015] (i.e. oral carbohydrates, glucagon, IV glucose or 
other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet change, medication 
error (i.e. overdose, mix-up between products, incorrect use of device), miscalculation of dose 
of anti-diabetic medication, other factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms
38
– Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
– Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
– General malaise: headache or malaise (feeling discomfort/unease)
!Other symptoms
The Investigator must review the diary for low SMPG values not reported as hypoglycaemic 
epi[INVESTIGATOR_1841] (see Section 2for relevant visits). The subject must be questioned whether any of the low 
values were severe i.e. whether the subject was able to self-treat or not. If the subject was not able 
to self-treat, it has to be reported as a se vere hypoglycaemic epi[INVESTIGATOR_36210] a hypogly caemic epi[INVESTIGATOR_36211].
Low SMPG values for non-severe hypoglycaemic epi[INVESTIGATOR_36212] a hypoglycaemic epi[INVESTIGATOR_36213] [ADDRESS_36093] be re-trained in how to report  hypoglycaemic epi[INVESTIGATOR_36214] e investigator identifies 
low SMPG values not reported as hypoglycaemic epi[INVESTIGATOR_1841].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 59 of 132
If the hypoglycaemic epi[INVESTIGATOR_36215], then an AE form and a safety 
information form (SIF) must also be filled in, see Section  12.
8.[ADDRESS_36094], and IgE anti-semaglutide antibodies will be analysed by a 
special laboratory and Novo Nordisk A/S (see Sections 8.4.8 ). For some of the analyses related to 
suspi[INVESTIGATOR_36216] a local laboratory must be used (see 
appendix B ). 
The handling, transportation and storage of biological samples are described in the laboratory 
manual (for central and special laboratory details see  Attachment I ).
Samples will be coded in order to keep subject identity anonymous.
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window stated in the flow chart (see Section 2). Please note that a laboratory 
sample pertaining to a specific visit must always be reported to that visit.
For some of the samples drawn during the trial, subjects will be asked to attend the site visits fasting 
(fasting for blood sampling is defined in Section 8.1.2 ).
The central laboratory will provide laboratory results to the investigator on an ongoing basis. 
However, anti-semaglutide antibody results will not be available to the investigator during the trial. 
These results will be provided to the investigator upon request after the completion of the clinical 
trial report (CTR). The laboratory provides results to the trial sites in the units preferred by [CONTACT_36294].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator.
The investigator must review all laboratory results for concomitant illnesses and AEs and report 
these according to Sections 8.2.[ADDRESS_36095] at the completion of the CTR, or according to 
local regulations, except samples obtained for antibody analysis. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36096] in recording the following data in the diary:
!date of first trial product administration
!hypoglycaemic epi[INVESTIGATOR_1841]
!changes in concomitant medication
!AEs
!SMPG 7-point profile
8.6.2 Training in the injection pen
An injection pen is used for s.c. administration of liraglutide/liraglutide placebo. The subjects must 
be trained in how to handle the injection pen when handed out the first time. Training must be 
repeated during the trial at regular intervals in order to ensure correct use of the injection pen. The 
following should be emphasised:
!Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!Priming the pen to ensure product flow 
!The needle should be kept in the skin while counting slowly to 6 (or as described in the 
direction for use) after the dose counter has returned to zero after injection. If the needle is 
removed too early then the full dose may not have been delivered. Always remove the needle 
after each injection and store the pen-injector with no needle attached.
The investigator must document that direction for use (DFU) is given to the subject verbally and in 
writing at the first dispensing visit (V2).
8.[ADDRESS_36097] compliance. 
Treatment compliance: Will be assessed by [CONTACT_36295]. Prior to visits 
where drug accountability is performed, the subject will be asked to return all used, partly used and 
unused trial products. The investigator must assess the amount of trial products returned compared 
to what was dispensed at the last dispensing visit and, in case of discrepancies, question the subject.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36098]’s medical record.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 62 of 132
9 Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM). 
Trial products must not be dispensed to any person not included in the trial. 
Liraglutide or liraglutide placebo must only be used, if it appear clear and colourless or almost 
colourless.
9.1 Trial products
The following trial products are considered as IMPs and will be provided by [CONTACT_3454] A/S, 
Denmark:
Table 9–[ADDRESS_36099] Strength Dosage formRoute of 
administrationContainer/
delivery device
Semaglutide 3 mg tablet3 mg
Tablet Oral Blister cardaSemaglutide 7 mg tablet7 mg
Semaglutide 14 mg tablet14 mg
Placebo tabletN/A
Liraglutide 6 mg/mL Solution for
injectionSubcutaneous
injection (s.c.)Pen-injector
Placebo injection N/A
aOne dosepack contains one blister card with 7 tablets
Metformin, SGLT-2 inhibitors and rescue medication are considered NIMPs and will not be 
supplied by [CONTACT_3454] A/S. However, during the 52-weeks treatment period and the 5 weeks 
follow-up period; the patients de-facto cost (actual patient cost, not covered by [CONTACT_36296]/any insurance) of SGLT-2-inhibitor and metformin (mono- or fixed dose combination 
products) will be reimbursed in accordance with local legislation and Ethics Committee approval.
For Japan only: During the treatment period, all anti-diabetic medication including pre-trial OADs 
will be reimbursed by [CONTACT_36297].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36100] dispensing visit (V2). Directions for use should be given to the subject at subsequent 
visits when judged necessary by [CONTACT_093]. The subjects must be trained in how to handle the 
injection pen when handed out the first time. Training must be repeated during the trial at regular 
intervals in order to ensure correct use of the injection pen.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 64 of 132
9.3 Storage 
Storage conditions of the trial products are outlined in Table 9–2 .
Table 9–2 Storage conditions for investigational medicinal products
*In-use time starts when the product is taken out of the refrigerator at subjects home
The investigator must ensure that trial product is kept under proper storage conditions, and  record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
For Japan only: The head of the study site or the trial product storage manager if assigned by [CONTACT_36298], record and evaluate 
the temperature.Trial productStorage conditions
(not-in-use)In-use conditionsIn-use time*
Semaglutide 3 mg 
tabletDo not store above 30ºC 
(86ºF)
Do not freeze
Do not refrigerate
Store in the original 
packageTake the tablet immediately 
after dispensation from blister 
card
Take the tablets whole: Do not 
break or chewN/ASemaglutide 7 mg 
tablet
Semaglutide 14 mg tablet
Placebo tablet
Liraglutide 6
mg/mLStore in a refrigerator
2°C to 8°C (36°F to 
46°F)
Protect from light
Do not freezeAt temperatures below 30°C 
or in a refrigerator 2°C to 8°C
US only: At room
temperature (59–86°F) or in a 
refrigerator (36°–46°F)
Protect from light
Do not freezeUse within one month
US only: Use within 30
daysPlacebo injectionsCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 65 of 132
9.4 Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.
For Japan only: Drug accountability is the responsibility of the head of the study site or the trial 
product storage manager if assigned by [CONTACT_36299].
Subjects must be instructed to return all used, partly used and unused trial products including empty 
packaging material at each dispensing visit.
Returned trial product (used/partly used and/or unused, expi[INVESTIGATOR_36217]) can be 
stored at room temperature and must be stored separately from non-allocated trial product. Non-
allocated trial product (including expi[INVESTIGATOR_36218]) must be accounted for at the latest 
at closure of trial site.
Drug accountability is performed by [CONTACT_36300]. Drug accountability must be done on tablet 
and pen injection level.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by [CONTACT_2037]. Destruction of 
products must be documented in the IWRS.
9.5 Auxiliary supplies
The following will be provided by [CONTACT_3454] A/S in accordance with the TMM:
!Direction For Use for pen-injector for trial product (liraglutide)
!Needles for the device (needles longer than [ADDRESS_36101] not be used)
!BG meter and BG meter auxiliaries
For Japan only: The trial sites are allowed to purchase and supply themselves with auxiliary 
supplies, if possible. BG meters must be the same model as supplied by [CONTACT_3454].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 66 of 132
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for:
!Screening
!Screening failure
!Randomisation
!Medication arrival
!Dispensing
!Treatment discontinuation
!Completion
!Code break
!Drug accountability
!Data change
IWRS user manuals will be provided to each trial site. DUNs will be allocated using the IWRS. It is 
important to dispense the exact allocated DUNs to a subject.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 67 of 132
11 Randomisation procedure and breaking of blinded codes
The trial is a double-blinded trial. A randomisation session will be carried out for all subjects using 
the IWRS. 
At the randomisation visit (V2), subjects meeting all eligibility criteria will be randomised to one of 
three parallel treatment arms as described in Section 5.1.
Randomisation will be stratified based on:
!Anti-diabetic background medication at screening (metformin alone, metformin in combination 
with SGLT-2 inhibitor)
!Descent (Japanese subjects, non-Japanese subjects)
to ensure a 2:2:1 distribution of the three treatment arms within the four strata.
The aim is to randomise a minimum of 125 subjects on a background medication including SGLT-2 
inhibitor, and a minimum of 75 Japanese subjects.
11.1 Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by [CONTACT_8784], 
record the reason, and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If the IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_36302] I. If the code has been 
broken the subject must discontinue treatment with trial product but be asked to continue in the trial 
(see Section 8.1.6 ). A treatment discontinuation session must be completed in the IWRS.
The laboratory responsible for antibody analysis and the responsible development bioanalysis 
scientist in Novo Nordisk will have access to the unblinding report in the IWRS .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 68 of 132
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
12.1.1 Adverse event
An adverse event (AE) is any untoward medical occurrence in a subject administered or using a 
product, and which does not necessarily have a causal relationship with this treatment or usage. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A CLAE: a clinical laboratory abnormality which is clinically significant, i.e. an abnormality 
that suggests a disease and/or organ toxicity and is of a severity that requires active 
management. Active management includes active treatment or further investigations, for 
example change of medicine dose or more frequent follow-up due to the abnormality.
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening or other trial procedures
performed before exposure to trial product (pre-existing conditions should be reported as 
medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity after the subject has signed the informed consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_36219], see Section 8.4.9 .
The following three definitions are used when assessing an AE:
!Severity 
–Mild – no or transient symptoms, no interference with the subject's daily activities.
–Moderate – marked symptoms, moderate interference with the subject's daily activities.
–Severe – considerable interference with the subject's daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
–Probable – Good reason and sufficient documentation to assume a causal relationship.
–Possible – A causal relationship is conceivable and cannot be dismissed.
–Unlikely – The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 69 of 132
!Final outcome
–Recovered/resolved – The subject has fully recovered, or by [CONTACT_36303]-related activity after the 
subject signed the informed consent.
–Recovering/resolving – The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–Recovered/resolved with sequelae – The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–Not recovered/not resolved – The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–Fatal – This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as ”recovered/resolved”, ”recovering/resolving”, ”recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE.
–Unknown – This term is only applicable if the subject is lost to follow-up.
12.1.2 Serious adverse event
An SAE is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] – based on appropriate medical judgement –
they may jeopardise the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd.  
a. The term ”life threatening” in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe.
b. The term ”hospi[INVESTIGATOR_11956]” is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or 
– Stays at the hospi[INVESTIGATOR_36223] 24 hoursCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36102]'s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospi[INVESTIGATOR_36224].
The following AEs must always be reported as an SAE using the important medical event criteria if 
no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_36225]
!risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where no 
alternative aetiology exists (Hy's law).
Additional assessments should be made for events meeting the criterion of Hy’s law as stated above 
(see Appendix B ). 
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 71 of 132
12.1.4 Medication errors
A medication error concerning trial products is defined as:
!Administration of wrong drug or use of wrong device. 
Note: Use of wrong DUN is not considered a medication error.
!Wrong route of administration, such as intramuscular instead of s.c.
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), misuse or 
abuse of trial product
!Accidental administration of a higher dose than intended. A higher dose is a dose of at least one 
tablet more than the intended dose and for pen injection a higher dose than 1.8 mg/day; 
however, the administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial subject were likely to happen as judged by [CONTACT_093], although 
they did not necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section [IP_ADDRESS] , 
12.1.[ADDRESS_36103] been pre-specified. See appendix B for details about these events and the additional 
information to report.
Some events in this trial will be adjudicated by [CONTACT_36304] 12.7.2 .
Table 12-1 lists AEs that require completion of specific event forms in the eCRFs and/or are subject 
to event adjudication.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 72 of 132
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject 
to event adjudication
Event Specific event form Event adjudication
Death No Yes
Acute coronary syndrome (myocardial infarction or 
hospi[INVESTIGATOR_36193])Yes Yes
Cerebrovascular event (stroke or transient ischaemic
attack)Yes Yes
Heart failure YesYes (only if requiring
hospi[INVESTIGATOR_11956])
Pancreatitis Yes Yes (only if acute pancreatitis)
Neoplasm (excluding thyroid neoplasm) Yes Yes (only if malignant)
Thyroid disease (including thyroid neoplasm) YesYes (only if malignant thyroid 
neoplasm or C-cell hyperplasia)
Renal event Yes Yes (only if acute kidney injury)
Hypersensitivity reaction Yes No
Acute gallstone disease Yes No
Medication error Yes No
Lactic acidosis Yes Yes
Creatine kinase (CK) > 10x UNL Yes No
Hepatic event defined as:
ALT or AST > 5 x UNL and total bilirubin ≤ [ADDRESS_36104] > 3 x UNL and total bilirubin > 2 x UNL*
Hepatic event leading to trial product discontinuation.Yes No
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 
x UNL and total bilirubin > 2 x UNL, where no alternative aetiology exists (Hy's law), this must be reported as an SAE 
using the important medical event criterion if no other seriousness criteria are applicable.
For details about specific event forms, see appendix B .
12.1.[ADDRESS_36105] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 73 of 132
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!All packaging material including labelling
!Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
Only technical complaints related to adverse events will be reported in the clinical trial report.  
12.[ADDRESS_36106]-treatment follow-up period (V14) for subjects on trial product or until the end of 
trial (V13 or V14A, whichever comes last) for the subjects who have discontinued trial product 
prematurely. Events for withdrawn subjects will be collected and reported until last trial related 
contact [CONTACT_1155]. The events must be recorded in the applicable eCRF forms in a timely 
manner, see timelines below and Figure 12–[ADDRESS_36107] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: "Have you experienced any problems since the last contact?"
All AEs, either observed by [CONTACT_36305], must be reported by [CONTACT_36306]. 
All AEs must be recorded by [CONTACT_36307]. The investigator should report 
the diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms in the eCRF.
For SAEs, a safety information form (SIF) must be completed in addition to the AE form. A SIF is 
a form to collect supplementary clinical information. If several symptoms or diagnoses occur as part 
of the same clinical pi[INVESTIGATOR_1103], one SIF can be used to describe all the SAEs. 
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event. See appendix B for details about the events and the additional information to 
report. In case any of these events fulfil the criteria for seriousness in Section 12.1, then the event 
should be reported as serious.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36108]. 
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the SIF within 5 calendar days of the investigator's 
first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in 
the eCRF. 
For SAEs requiring reporting on a specific event form: In addition to the above, the specific 
event form within [ADDRESS_36109] knowledge of the AE.
!Events for adjudication : The adjudication form should be completed within 14 calendar days
of the investigator’s first knowledge of the AE, see Section 12.7.[ADDRESS_36110] details (fax, telephone, e-mail and address) are provided in the investigator trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 75 of 132
AE identifiedDoes the AE require 
a sp ecific even t 
form?Is the  AE  subject to 
adjudication and/or 
is the outcom e 
fatal?
AE  form < 24 hours
SIF < 5 calendar days
Specific event form  
For SAEs:
< 14 calendar days
Is the AE serious or 
non-serious?
AE form
Adjudication form
< 14 calendar da ys
Source data < 4 weeks
Non-seriousSerious
NoYes Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar da ys
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are described in Section 12.1.4, 12.1.5 and appendix B.
AEs  for adjudi ca tion are de scribed i n Secti on 12.7.2
AE: Adverse event  SAE: Serious adverse event  SIF: Safety Information form 
No additional action
 No additional actionNo
Figure 12–1 Reporting of AEs
Novo Nordisk A/S assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference
documents:
!IB for oral Semaglutide (NN9924)24and Victoza ®; current versions and any updates 
thereto.
!CCDS (Company Core Data Sheet) for Liraglutide ; current versions and any updates 
thereto.
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454] A/S:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including European Medicines Agency (EMA), of trial product-related S[LOCATION_003]Rs. In addition, Novo 
Nordisk will inform the IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local 
requirement and ICH GCP
1, unless locally this is an obligation of the investigator.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 76 of 132
Novo Nordisk A/S products used as concomitant medication or non-investigational medicinal 
product:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product or concomitant medication in the trial, it is important that the 
suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the 
SIF. Novo Nordisk may need to report this AE to relevant regulatory authorities.
12.[ADDRESS_36111] be reported to Novo Nordisk according to the following:
!SAEs : All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of 
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed the 
follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator's first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
!Non-serious AEs : Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the 
end of the follow-up period stated in the protocol, whichever comes first, and until all queries 
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome 
of “recovering/resolving” when the subject has completed the follow-up period and is expected 
by [CONTACT_36308].
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_36112].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 77 of 132
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial.
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
All technical complaints on any of the following products: 
!semaglutide 3 mg/7 mg/14 mg or placebo tablets
!liraglutide or placebo pre-filled pen-injector
!Novo Nordisk needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to the Customer Complaint Center, Novo Nordisk.
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs or SAEs.
Technical complaints must be reported on a separate technical complaint form. A technical 
complaint form for each code or lot number must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_36113] the technical complaint sample and notify the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36114](s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age .
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant .
The following must be collected and reported by [CONTACT_36309] – electronically 
(e.g. in PDF format), or by [CONTACT_36310] :
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further
information has to be reported for the female subject on Maternal Form 2. In addition,
information from the male partner has to be reported on the Paternal Form, after an informed
consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the
investigator's first knowledge of initial or follow-up information.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 79 of 132
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!AE formawithin 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!AE formawithin 24 hours of the investigator's first knowledge of the SAE. 
!SIF within 5 calendar days of the investigator's first knowledge of the SAE.
!SAE follow-up information to the AE form and/or SIF within 24 hours of the 
investigator's first knowledge of the follow-up information.
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_36115] .
12.6 Precautions and/or overdose
There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.
There is a potential risk of hypoglycaemia during dosing with semaglutide. The typi[INVESTIGATOR_36226] a non-severe hypoglycaemia include: hunger, slight headache, nausea, light-
headedness, palpi[INVESTIGATOR_36227]. Symptoms  of non-severe hypogl ycaemia should be treated 
by [CONTACT_36311]. 
Severe hypoglycaemia resulting in  loss of consciousness should be treated according to best 
available medical practise. 
One case of accidental overdose of oral semaglutide was reported in the NN9924-[ADDRESS_36116]  and was thus treated with 20 mg of CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36117] 
wished to continue in the trial. No symptoms  of hypoglycaemia or  any other symptoms or signs 
were noted.  
For further details please see the current edition of the IB for oral administration of semaglutide 
(NN9924), edition 624, and any updates hereof.
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal oral semaglutide safety committee to perform ongoing 
safety surveillance. The oral semaglutide safety committee may recommend unblinding of any data 
for further analysis, and in this case an independent ad hoc group will be established in order to 
maintain the blinding of the trial personnel .
12.7.2 Event adjudication committee
An independent external event adjudication committee (EAC) is established to perform validation 
of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of 
pre-defined clinical data related to the specific AE. Pre-defined clinical data consist of copi[INVESTIGATOR_36228].
The EAC is composed of permanent members covering required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk . 
The events are reviewed by [CONTACT_36312] a blinded manner. The EAC will have no authorisations to 
impact on trial conduct, trial protocol or amendments.
The EAC works in accordance with written guidelines included in the EAC Charter describing in 
details the composition, tasks, responsibilities and work processes of the committee.
The events outlined in Table 12–[ADDRESS_36118] been selected for adjudication in order to obtain an external 
independent validation of the diagnosis. In addition, cardiovascular events are being adjudicated 
according to U.S. Food and Drug Administration (FDA) requirements42.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 81 of 132
The EAC will review copi[INVESTIGATOR_36229] (translated if necessary) of medical documentation received 
in the adjudication packages (e.g. x-rays, ECGs, ultrasound images, discharge summaries, 
pathology reports and death certificates). The investigator must provide medical documentation as 
soon as possible, when they receive the request from Novo Nordisk or the event adjudication 
vendor.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 82 of 132
The AEs for adjudication are listed in Table 12–2 :
Table 12–2 Adverse events for adjudication
Events Description Adjudication outcome
Death* !All-cause death !Cardiovascular death 
(including undetermined 
cause of death)
!Non-cardiovascular death
Acute Coronary Syndrome !Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP)!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospi[INVESTIGATOR_36230] !Epi[INVESTIGATOR_36231], spi[INVESTIGATOR_1831], or 
retinal vascular injury as a result of 
haemorrhage or infarction
!Transient Ischaemic Attack (TIA) is defined as 
a transient epi[INVESTIGATOR_1865] (< 24 hours) of focal 
neurological dysfunction caused by [CONTACT_36313], spi[INVESTIGATOR_36232], or retinal ischaemia, without acute 
infarction!Ischaemic stroke
!Haemorrhagic stroke
!Undetermined stroke
!TIA
Heart failure requiring 
hospi[INVESTIGATOR_11956]!Hospi[INVESTIGATOR_36233] a primary diagnosis of 
heart failure (new epi[INVESTIGATOR_36234])!Heart failure requiring 
hospi[INVESTIGATOR_36235]:
!Abdominal pain consistent with acute 
pancreatitis (acute onset of a persistent, severe, 
epi[INVESTIGATOR_36236])
!Serum lipase activity (and/or amylase activity) 
at least three times greater than the UNL
!Characteristic findings of acute pancreatitis on 
imagingAcute pancreatitis
!Mild
!Moderately severe 
!Severe
Malignant neoplasm Malignant neoplasms are defined as
!neoplasms in which abnormal cells divide 
without control and can invade nearby [CONTACT_36314]/or spread to other parts of the body through 
the blood and lymph systems
Thyroid neoplasms are excluded in this event 
category!Malignant neoplasm
Thyroid disease, if malignant 
thyroid neoplasm or C-cell Malignant thyroid neoplasms are defined as 
!thyroid neoplasms in which abnormal cells !Malignant thyroid 
neoplasmCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 83 of 132
hyperplasia divide without control and can invade nearby 
[CONTACT_36315]/or spread to other parts of the body 
through the blood and lymph systems
!C-cell hyperplasia, defined as hyperplasia of the 
parafollicular C-cells of the thyroid gland!C-cell hyperplasia
Acute kidney injury Acute kidney injury43is defined as any of the 
following (not graded):
!Increase in serum creatinine by ≥ 0.3 mg/dL 
(≥26.5 μmol/L) within 48 hours, or
!Increase in serum creatinine to ≥ 1.[ADDRESS_36119] 
occurred within the prior 7 days, or
!Urine volume < 0.5 mL/kg/h for 6 hours!Acute kidney injury
Lactic acidosis !Lactic acidosis is characterized by [CONTACT_36316]!Lactic acidosis
*Death is not a separate event, but an outcome
There are different processes for capturing events for adjudication:
!Direct reporting by [CONTACT_1697]:
oAll AEs need to be assessed by [CONTACT_36317]. If the 
AE category selected is in scope for adjudication, the event specific adjudication form in 
the eCRF will be populated for sites to complete
oAEs with fatal outcome
!Screening: 
oAll AEs will be screened by [CONTACT_36318], the investigator will be asked to provide additional information such as an 
alternative aetiology, underlying cause(s) and/or clinical details.
oAll ECGs will be centrally read. If the central reading conclusion is suggestive of new 
MI, the ECG adjudication form will be populated for sites to complete for all post-
baseline ECGs.
!EAC identified events:
oThe EAC can decide to have an AE adjudicated even if not initially reported as an event 
for adjudication by [CONTACT_093].
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
AEs for adjudication must be reported according to Section 12.2. In addition, the specific 
adjudication form should be completed within 14 calendar days of the investigator's first knowledge CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 84 of 132
of the AE and all relevant predefined documents provided within 4 weeks according to instructions 
in the event adjudication site manual.
The assessment made by [CONTACT_36319]. However, the adjudication made by [CONTACT_36320], given its 
independent analysis of each event, will be attributed with greater importance of the two. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36120] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRF):
!Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!AE forms 
!SIFs
!Technical complaint forms (also to be used to report complaints that are not subject related (e.g. 
discovered at trial site before allocation)).
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] "ND" (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by [CONTACT_565] "NA" (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_36321], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by [CONTACT_36322]'s delegated staff.
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction. If corrections are made by [CONTACT_093]'s delegated staff after the date the investigator 
has signed the case book, the case book must be signed and dated again by [CONTACT_093] .
13.[ADDRESS_36121] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36122] been entered into 
the eCRF no later than 3 days after LSLV at the site in order to ensure the planned lock of the 
database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site .When the final CTR is 
available, the data will be archived by [CONTACT_3454] A/S.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36123] monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and Good Clinical Practice (GCP), but will not exceed 12 weeks until 
LSLV at the trial site (for trial sites with active subjects (defined as subjects in screening, treatment 
or follow-up)).
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]).
All data must be verifiable in source documentation other than the eCRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].
The original of the completed diaries and/or PROs must not be removed from the trial site, unless 
they form part of the eCRF and a copy is kept at the site.
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures:
!Date for obtaining informed consent.
!Reason for screening failure
Monitors will review the subject's medical records and other source data (e.g. the diaries and PROs) 
to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, 
the investigator must be questioned about these.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 88 of 132
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36124] Research Organisation (CRO). 
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks. 
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by [CONTACT_36325]. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
[CONTACT_5737], regional and national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36125] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 91 of 132
17 Statistical considerations
General considerations
If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before 
database lock.
The blinding of the randomised treatments will be maintained until the database has been released 
for statistical analysis. Data from all sites will be analysed and reported together. 
In statistical analyses where stratification is included, the two combinations of anti-diabetic 
background medication at screening (metformin or metformin+SGLT-2 inhibitor) will be included 
based on the actual information collected through the eCRF. In case of missing eCRF information 
the information collected from the IWRS system will be used. The information regarding descent 
(Japanese subjects/non-Japanese subjects) will be included based on country details from the eCRF. 
In the statistical analyses the stratification factor will refer to anti-diabetic background medication
at screening. Descent (Japanese subjects/non-Japanese subjects) will be included in the statistical 
analyses as part of region.
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.
Laboratory values below the lower limit of quantification (LLoQ) will be set to ½LLoQ. Number of 
values below LLoQ by [CONTACT_36326].
The primary and confirmatory efficacy endpoints will be evaluated at week 26. This approach is 
expected to result in a lower proportion of missing data, use of rescue medication and premature 
treatment discontinuations, compared to the expected proportion of missing data, use of rescue 
medication and premature treatment discontinuation at week 52, and therefore considered a 
meaningful representation and confirmation of the effect of oral semaglutide. 
Results from a statistical analysis will as a minimum be presented by [CONTACT_36327]-sided 95% confidence intervals and p-
values corresponding to two-sided tests of no difference.
!oral semaglutide 14 mg vs. placebo 
!oral semaglutide 14 mg vs. liraglutide 1.8 mg 
If no statistical analysis is specified, data will be presented using relevant summary statistics.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 92 of 132
Primary and secondary estimands
Two estimands addressing different aspects of the trial objective will be defined; a primary de-facto 
(effectiveness) estimand and a secondary de-jure (efficacy) estimand: 
!Primary estimand
– de facto treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week 26 for all randomised subjects regardless of adherence to randomised 
treatment and initiation of rescue medication
The primary de facto estimand assesses the expected glycaemic benefit in a future population that 
results from subjects initiating treatment with oral semaglutide including potential rescue 
medication(s) and the expected glycaemic benefit compared to initiating treatment with liraglutide 
including potential rescue medication(s). Generalisation of this estimand depends among other 
things on the extent to which the use of rescue medication in this trial reflects clinical practice and 
the adherence to trial product administration in this trial reflects the behaviour of the target 
population. Accordingly, data collected regardless of discontinuation of trial product or initiation of 
rescue medication(s) will be used to draw inference. 
!Secondary estimand 
– de-jure treatment difference (oral semaglutide versus placebo and oral semaglutide versus 
liraglutide) at week [ADDRESS_36126] 
even though subjects are intended to stay in the trial regardless of treatment status and initiation of 
rescue medication(s), is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will be due to withdrawal from trial or lost to follow-up.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 93 of 132
When estimating the secondary estimand, the proportion of missing data is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s) 
will be set to missing. The 20% of missing data is based on the liraglutide phase 3 trial (NN2211-
1572), the oral semaglutide phase 2 trial (NN9924-3790) that indicates that a low starting dose with 
gradual dose escalation diminishes GI AEs compared with more aggressive dosing regimens. 
Across treatment arms the main reasons for missing data are expected to be early treatment 
discontinuation due to AEs (GI AEs for oral semaglutide and liraglutide) and initiation of rescue 
medication. Initiation of rescue medication is expected to be more frequent in the placebo arm than 
for the oral semaglutide and liraglutide arms. A higher proportion of subjects are expected to 
discontinue treatment due to AEs in the oral semaglutide and liraglutide arms, compared to the 
placebo arm. So overall the frequency of missing data is expected to be similar across treatment 
arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by [CONTACT_2939].
17.[ADDRESS_36127], a similar trial LEAD-2 ([STUDY_ID_REMOVED]) 
where liraglutide was used as add on to metformin was reviewed. Based on this trials, the chosen 
margin of 0.[ADDRESS_36128] consistently 
established that liraglutide is an effective anti-diabetic drug. Therefore, lack of trial sensitivity with 
liraglutide as comparator is not anticipated to be an issue in this trial. 
The primary endpoint is change from baseline to week 26 in HbA 1c. For HbA 1c, superiority of oral 
semaglutide vs. placebo and both non-inferiority and superiority of oral semaglutide vs. liraglutide 
are planned to be tested. The confirmatory secondary endpoint is change from baseline to week 26 
in body weight (kg). For body weight, superiority of oral semaglutide vs. placebo and oral 
semaglutide vs. liraglutide are planned to be tested. 
The sample size calculation is made to ensure a power of at least 90% for testing the below four out 
of the five pre-specified confirmatory hypotheses shown in Figure 17–1 . The closed testing
procedure described in Bretz et al. (2011)44is used to control the overall type I error at a nominal 
two-sided 5% level. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 94 of 132
The four hypotheses are
!HbA 1c superiority of oral semaglutide vs. placebo
!HbA 1cnon-inferiority of oral semaglutide vs. liraglutide (margin 0.4%)
!Body weight superiority of oral semaglutide vs. placebo 
!Body weight superiority of oral semaglutide vs. liraglutide 
The statistical testing strategy is based on the following two principles:
!To demonstrate glycaemic effect of oral semaglutide compared to placebo
!Glycaemic effect compared to liraglutide must be established in terms of HbA 1cnon-inferiority 
before testing for added benefits in terms of HbA1c superiority and/or body weight superiority.
The sample size is calculated using the calcPower function in the R package, gMCP45using [ZIP_CODE] 
simulations. All of the five pre-specified confirmatory tests are assumed to be independent. Since 
some of the tests are positive correlated, the assumption of independence is viewed as conservative.
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the standard 
deviations (SD) are given in Table 17–1 .
These assumptions are primarily based on the oral semaglutide phase 2 results (NN9924-3790), 
liraglutide phase 3 trial results (Victoza® US prescribing information) and supported by [CONTACT_36328] s.c. semaglutide phase 2 trial (NN9535-1821). 
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who are expected to discontinue trial product or 
initiate rescue medication and for the 10% of subjects who are expected to have actual missing data. 
The treatment effects used in the sample size calculation will be adjusted according to a 75% 
smaller effect in these subjects. For the 10% of the subjects with missing data, the non-inferiority 
margin of 0.4% for HbA 1cis added to the imputed values, when testing for non-inferiority. The 
adjusted treatment effects for testing non-inferiority (HbA 1c oral semaglutide versus liraglutide 
only) and superiority are as described below:
!Non-inferiority 
– 0.8×TE + 0.2×TE×0.25 + non-inferiority margin×0.1
!Superiority
– 0.8×TE + 0.2×TE×0.25 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 95 of 132
Table 17–[ADDRESS_36129] 
(TE)Adjusted TE, 
non-inferiorityAdjusted TE, 
superiorityStandard 
deviation Non-
inferiority 
margin
Placebo HbA 1c −1.0% −0.85% 1.1%
Liraglutide HbA 1c 0% +0.04% 0% 1.1% 0.4%
Placebo Body weight −3kg −2.55kg 4kg
Liraglutide Body weight −1.5kg −1.275kg 4kg
With the above assumptions using a 2:2:1 randomisation, allocating 276 subjects to each of the oral 
semaglutide and the liraglutide arms and allocating 138 subjects to the placebo arm, provides 90% 
power to jointly confirm HbA 1csuperiority of oral semaglutide vs. placebo, HbA 1cnon-inferiority 
of oral semaglutide vs. liraglutide, body weight superiority of oral semaglutide vs. placebo and 
body weight superiority of oral semaglutide vs. liraglutide. In total 690 subjects are planned to be 
randomised. Calculated powers for individual hypotheses are presented in Table 17–2 . 
Table 17–2 Calculated powers for individual hypotheses
Comparator: placeboliraglutide
Statistical test:HbA 1c
superiorityBody weight
superiorityHbA 1c
non-inferiorityHbA 1csuperiorityBody weight
superiority
Power: > 99% 97% 97% 2% 91%CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 96 of 132
Figure 17–1 Graphical illustration of the closed testing procedure
The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA 1csuperiority test vs. placebo. The 
local significance level ( α-local) will be reallocated if a hypothesis is confirmed according to the weight given by [CONTACT_36329] (hypotheses).The sample size is based on the hypotheses in the dark boxes.
17.2 Definition of analysis sets
The following analysis sets will be defined:
Full analysis set (FAS): Includes all randomised subjects. Subjects in the FAS will contribute to 
the evaluation “as randomised”.
Safety analysis set (SAS): Includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation “as treated”.
Per protocol (PP) analysis set: Includes all subjects in the FAS who fulfils the following criteria
!have not violated any inclusion criteria
!have not fulfilled any exclusion criteria
!have a baseline HbA 1cmeasurement
!is exposed to trial product and have at least one HbA 1cmeasurement at or after week 14
Subjects in the PP analysis set will, as in the SAS, contribute to the analysis “as treated”.
       =0HbA 1c (%)
Non-inferiority vs. liraglutide
       =0HbA 1c (%)
Superiority vs. liraglutide
       =0Body weight (kg)
Superiority vs. liraglutide
1
 12 
1
1
       =0 . 0 5HbA 1c (%)
Superiority vs. placebo
1
       =0Body weight (kg)
Superiority vs. placebo12 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 97 of 132
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial. The full duration of the trial is defined as up to and including
!the follow-up visit (V14) for subjects on trial product
!the latest occurring visit of the end-of-treatment visit (V13) or the follow-up premature 
discontinuation visit (V14A), for subjects who have discontinued trial product prematurely.
Subjects and data to be used in an analysis will be selected in a two-step manner.
!Firstly, subjects will be selected based on the specified analysis set
!Secondly, data points on the selected subjects from the first step will be selected based on the 
specified observation period
Definition of the observation periods:
In-trial: This observation period represents the time period where subjects are considered to be in 
the trial, regardless of discontinuation of trial product or initiation of rescue medication. The in-trial 
observation period starts at randomisation (as registered in the IWRS) and ends at the date of
!the last direct subject-site contact, which is scheduled to take place [ADDRESS_36130] at the follow-up visit. 
!withdrawal for subjects who withdraw their informed consent
!the last subject-investigator contact [CONTACT_36330]-up
!death for subjects who dies before any of the above 
On-treatment : This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs, anti-semaglutide antibodies, and 
AEs including hypoglycaemic epi[INVESTIGATOR_1841], the observation period ends at the first date of any of the 
following:
!the follow-up visit (V14)
!the follow-up prematurely discontinuation visit (V14A)
!the last date on trial product +38 days (5 weeks follow-up period + 3 days visit window)
!the end-date for the in-trial observation periodCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36131] 
corresponding to approximately five half-lives of oral semaglutide. The visit window for the follow-
up visit is +3 days.
For efficacy and other safety assessments (laboratory assessments, physical examination and vital 
signs) the observation period ends at the last date on trial product +3 days. This will be used in 
order to ensure specificity to reversible effects of treatment
On-treatment without rescue medication: This observation period is a subset of the on-treatment 
observation period, where subjects are considered treated with trial product, but has not initiated 
any rescue medications. The on-treatment without rescue medication observation period starts at 
first date on trial product and the observation period ends at the first date of any of the following:
!the last dose of trial product +3 days
!initiation of rescue medication
The in-trial observation period will be the primary observation period when estimating the primary 
estimand. The on-treatment without rescue medication observation period will be the primary 
observation period when estimating the secondary estimand. The on-treatment observation period 
will be considered supportive for evaluating efficacy. Safety will be evaluated based on the in-trial 
and the on-treatment observation periods.
Data points collected outside an observation period will be treated as missing in the analysis. 
Baseline data will always be included in an observation period. For adjudicated events, the onset 
date will be the EAC adjudicated onset date. 
Before data are locked for statistical analysis and the randomisation code is broken, a review of all 
data will take place. Any decision to exclude either a subject or single observations from the 
statistical analysis is the joint responsibility of the members of the Novo Nordisk study group. 
Exclusion of data from analyses should be used restrictively, and normally no data should be 
excluded from the FAS. The subjects or observations to be excluded, and the reasons for their 
exclusion must be documented and signed by [CONTACT_36331]. The subjects 
and observations excluded from analysis sets, and the reason for this, will be described in the 
clinical trial report.
Confirmatory hypotheses 
For the primary HbA 1cendpoint and the confirmatory sec ondary body weight  endpoint the 
following confirmatory one-sided hypotheses are planned to be tested for oral semaglutide versus 
placebo (superiority) and oral semaglutide versus liraglutide (non-inferiority and superiority). Let 
the mean treatment difference be defined as μ = (oral semaglutide minus placebo or oral 
semaglutide minus liraglutide):CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 99 of 132
!HbA 1cnon-inferiority, using a non-inferiority margin of 0.4% (only vs. liraglutide) 
oH0: μ ≥ 0.4% against H a: μ < 0.4%
!HbA 1csuperiority
oH0: μ ≥ 0.0% against H a: μ < 0.0%
!Body weight superiority
oH0: μ ≥ 0.0kg against H a: μ < 0.0kg
Operationally, the hypotheses will be evaluated by [CONTACT_1192]-sided tests.  
Multiplicity and criteria for confirming hypotheses
The type I error for testing the five confirmatory hypotheses related to the HbA 1cand body weight 
endpoints will be preserved in the strong sense at 5 % (two-sided) using the weighted Bonferroni-
based closed testing procedure described in Bretz et al. (2011)44and outlined in Figure 17–[ADDRESS_36132] hypothesis to be tested is superiority of HbA 1cversus placebo. It will be tested at the 
overall significance level (5 %) while allocating 0 % local significance level to the remaining 
hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed the significance level 
will be reallocated according to the weight and the direction of the edges going from the confirmed 
hypothesis to the next hypotheses as specified in Figure 17–1 . Each of the following hypotheses 
will be tested at their local significance level ( α-local). This process will be repeated until no further 
hypotheses can be confirmed. 
Non-inferiority and/or superiority will be considered confirmed if the mean treatment difference is 
supporting the corresponding alternative hypothesis and the two-sided p-value from the primary 
analysis of the primary estimand is strictly below its local two-sided significance level as defined by 
[CONTACT_36332] 17–1 . This is equivalent to using a one-sided p-value 
(nominal α= 0.025) and a one-sided 2.5 % overall significance level in the closed testing procedure.
17.3 Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA 1c.
17.3.1 Primary analysis for the primary estimand 
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR) within the groups used for imputation. Imputation of missing data at week 26 will be done within 6 groups of subjects defined by [CONTACT_36333], and whether subjects at 
week 26 (i) have discontinued treatment or initiated rescue medication or (ii) are still on treatment CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36133] described by [CONTACT_36334] 26 are similar in terms of randomised treatment arm and treatment adherence/rescue 
medication status.
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with stratification factor and region as categorical fixed 
effects and baseline HbA 1cmeasurement as a covariate will be fitted to observed values of the 
change from baseline in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_36134] with missing week 26 data based on stratification factor and region as categorical and 
baseline HbA 1c. Thus, 100 complete data sets will be generated including observed and imputed 
values.
Analysis used for confirming superiority versus placebo/liraglutide at week 26:
For each of the 100 (now complete) imputed data sets, the change from baseline to week 26 will be 
analysed using an ANCOVA with treatment, stratification factor and region as categorical fixed effects and baseline HbA
1cas covariate. The results obtained from analysing the datasets will be 
combined using Rubin’s rule46to draw inference.
Analysis used for confirming non-inferiority versus liraglutide at week 26:
Prior to analysing the data using the same model and approach as used for confirming superiority 
(see above), a value of 0.4% (the non-inferiority margin) will be added to imputed values at week 
[ADDRESS_36135]-baseline measurements up
to and including week 26 from the on-treatment without rescue medication observation period. The 
primary analysis for the secondary estimand will be a Mixed Model for Repeated Measurements 
(MMRM). A restricted maximum likelihood (REML) will be used. The model will include all post 
baseline HbA
1cmeasurements collected at scheduled visits up to and including week [ADDRESS_36136] will be 
employed, assuming measurements from different subjects are independent. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 101 of 132
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the 
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data. 
17.3.[ADDRESS_36137] of missing data. Since conservatism, i.e. avoiding bias 
in favour of oral semaglutide, depends on the context, separate sensitivity analyses will be made for 
non-inferiority and superiority testing.
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, three additional sensitivity analyses for the primary analysis 
will be described that are not based on the pattern mixture model approach (see section [IP_ADDRESS] ).
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses: 
!A comparator multiple imputation analysis based on FAS using the in-trial observation period 
(superiority).
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period (superiority).
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the in-trial observation period 
(non-inferiority and superiority).
!A MMRM analysis (the primary analysis for the secondary estimand) based on FAS using the 
in-trial observation period (non-inferiority and superiority).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 102 of 132
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses:
!A comparator multiple imputation analysis based on FAS using the on-treatment without rescue 
medication observation period (superiority).
!A comparator multiple imputation analysis based on FAS using the on-treatment observation 
period (superiority). This sensitivity analysis aims to compare oral semaglutide versus placebo 
and versus liraglutide for subjects who adhere to treatment regardless of whether or not rescue 
medication has been initiated.
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the on-treatment without rescue medication 
observation period (superiority).
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period (non-inferiority and superiority).
[IP_ADDRESS] Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA 1cresults by [CONTACT_36335], while maintaining the missing data assumption for the comparator 
(placebo or liraglutide depending on the hypothesis). 
!Comparator multiple imputation analysis: In this sensitivity analysis missing data at week 
[ADDRESS_36138] this imputation approach removes the treatment 
difference between oral semaglutide and comparator for all subjects randomised to oral 
semaglutide, given that oral semaglutide is better than the comparator. Due to the potential 
lack of sensitivity for testing non-inferiority this sensitivity analysis will only be used to 
evaluate the robustness of HbA 1csuperiority conclusion.
!Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis missing data at week 26 for subjects who 
discontinue oral semaglutide treatment due to treatment related AE(s) will be imputed to 
resemble the distribution of the week [ADDRESS_36139] sensitivity analysis. Due to the potential lack of sensitivity for testing non-inferiority 
this sensitivity analysis will only be used to evaluate the robustness of HbA 1csuperiority 
conclusion.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 103 of 132
!Tippi[INVESTIGATOR_007]-point multiple imputation analysis: In this sensitivity analysis, missing data will 
first be imputed according to the primary analysis. Secondly, for the oral semaglutide 
treatment arm a penalty will be added to the imputed values at week 26. The approach is to 
gradually increase this penalty until the HbA 1cconclusion from the primary analysis is 
changed. The specific value of the penalty that changes the conclusion will be used to 
evaluate the robustness of the primary analysis result. This sensitivity analysis will be used 
for evaluating the robustness of the HbA 1c non-inferiority and superiority conclusions.
[IP_ADDRESS] Other sensitivity analyses
The following additional sensitivity analyses will be specified
!Per-protocol analysis : This sensitivity will be based on the per-protocol analysis set. Data 
from the on-treatment without rescue medication observation period will be analysed using 
the primary analysis approach for the primary estimand. This sensitivity analysis will be 
used to evaluate the robustness of the HbA 1c non-inferiority conclusions.
!Complete case analysis: This sensitivity analysis will be based on the on-treatment without 
rescue medication observation period and include subjects in the FAS who have a valid 
HbA 1c measurement at week 26. The change from baseline to week 26 in HbA 1cwill be 
analysed by a linear normal model (ANCOVA) with treatment, stratification factor and 
region as categorical fixed effects and baseline HbA 1cas a covariate. This sensitivity 
analysis will be used to evaluate the robustness of the HbA 1c non-inferiority conclusions. 
!Last observation carried forward (LOCF) analysis: This sensitivity analysis will be based 
on the FAS using the on-treatment without rescue medication observation period. The 
change from baseline to week 26 in HbA 1cwill be analysed by a linear normal model 
(ANCOVA) with treatment, stratification factor and region as categorical fixed effects and 
baseline HbA 1cas a covariate. This sensitivity analysis will be used for evaluating the 
robustness of the HbA 1c non-inferiority and superiority conclusions. 
[IP_ADDRESS] Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the 
trial results for HbA 1c. Due to the large number of sensitivity analyses and their inherent 
conservative nature, it will not be a requirement that all confirmatory hypotheses are consistently 
confirmed across the sensitivity analyses. Thus, no absolute success criteria will be pre-defined for 
each sensitivity analysis. The sensitivity results in totality will be used to substantiate the credibility 
of the trial results.
17.4 Secondary endpoints
17.4.1 Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 104 of 132
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA 1cendpoint. Body weight will only be tested for superiority. Baseline body weight 
will be used as a covariate instead of baseline HbA 1cin both the multiple imputation and analysis 
model.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two-sided significance level resulting from the closed testing procedure in 
Figure 17–1 . Sensitivity analyses similar to the ones pre-specified for testing superiority for the 
primary HbA 1cendpoint will be made to evaluate the robustness of the body weight results.
17.4.2 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for
!the primary estimand based on FAS using the in-trial observation period
!the secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
No sensitivity analyses are planned for these. [IP_ADDRESS] Continuous efficacy endpoints
Change from baseline to week 52 in:
!HbA
1c
!Body weight (kg)
Change from baseline to week 26 and week 52 in:
!Body weight (%)
!FPG
!BMI
!Waist circumference
!Fasting lipid profiles (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
BMI will be calculated based on body weight and height based on the formulae:
BMI kg/m2= body weight (kg)/(Height (m) x Height (m)) or (kg/m2= [lb/in2x 703])CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 105 of 132
Change from baseline to week 26 and week 52 in 7-point self-measured plasma glucose (SMPG) 
profile:
!Mean 7-point profile; defined as the area under the profile, calculated using the trapezoidal 
method, divided by [CONTACT_36336]
!Mean postprandial increment (during all meals)
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile 
endpoints will be log-transformed prior to analysis with the associated log-transformed baseline 
value as a covariate.
For evaluation of the primary estimand the analysis will be performed separately for week [ADDRESS_36140]-baseline measurement up to and including week 52. From this model the estimated 
treatment differences (ratios) will be presented at week 26 (except for HbA 1cand body weight), and 
week 52 with 95 % confidence intervals and two-sided p-values for test of no difference.
Binary efficacy endpoints
If a subject after week 26 achieves (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) (ADA) target
!HbA 1c≤ 6.5 % (48 mmol/mol) (AACE) target
!HbA 1c reduction ≥ 1 % (10.9 mmol/mol)
!Weight loss ≥ 3 %
!Weight loss ≥ 5 %
!Weight loss ≥ 10 %
!HbA 1c< 7.0 % (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemia) and no weight gain
!HbA 1creduction ≥ 1 % (10.9 mmol/mol) and weight loss ≥ 3 %
The above eight endpoints will also be evaluated after week 52.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 106 of 132
The above eight binary endpoints will be analysed using a logistic regression model with treatment 
and region as fixed effects and baseline response as covariate (i.e. baseline HbA1c for binary 
HbA1c endpoints, baseline weight for weight endpoints and both baseline HbA1c and baseline 
weight for the binary endpoint that combines both parameters). To account for missing data, the 
analysis will be made using a sequential multiple imputation approach as described below:
!Multiple imputed data sets (100) will be created in which missing values for the underlying 
continuous assessments are imputed by [CONTACT_36337]/rescue 
status assuming MAR and as described in section 17.3.1 for the primary estimand and by 
[CONTACT_36338] 17.3.2 for the secondary 
estimand.
!The binary endpoint will be created for each of the 100 complete data sets
Each of the created complete data set will be analysed with the logistic model and inference will be 
drawn using Rubin’s rule46.
Time to event endpoint
!Time to rescue medication
Subjects completing the study without need for rescue medication will be censored at the time point 
of the (actual) last date on trial product. The start time is first date on trial product. Time to rescue 
medication will be described and compared for oral semaglutide versus placebo and oral 
semaglutide versus liraglutide using likelihood ratio tests obtained from a proportional Cox hazards 
model with treatment, stratification factor and region as categorical fixed effects and baseline 
HbA 1cas covariate. From this analysis the estimated Hazard ratios between semaglutide and 
placebo and between semaglutide and liraglutide will be presented together with 95 % confidence 
intervals and two-sided p-values for test of no difference.
[IP_ADDRESS] Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and 
the in-trial observation period unless otherwise stated. The following endpoints are used to support 
the safety objective:
Adverse events 
!Number of TEAEs during exposure to trial product, assessed up to approximately [ADDRESS_36141] recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) coding. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 107 of 132
A TEAE is defined as an AE with onset in the on-treatment observation period (see definition of 
observation periods in Section 12).
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. The development over time in 
gastrointestinal AEs will be presented graphically.
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!Amylase
!Lipase
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed 
separately as described above for continuous efficacy endpoints. Results will be presented at week 26 and 52. Amylase and lipase endpoints will be log-transformed prior to analysis with the 
associated log-transformed baseline value as a covariate.
Change from baseline to week 26 and week 52 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination (week 52 only)
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeksCONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 108 of 132
!Anti-semaglutide binding antibody levels
The above safety endpoints will be summarised descriptively by [CONTACT_31703]. The binary
safety endpoints will be summarised as counts and relative frequencies. Calcitonin will also be 
presented by [CONTACT_547]. 
Hypoglycaemia
!Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_36184], assessed up to approximately 57 weeks
!Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36237], assessed up to approximately 57 weeks (yes/no) 
Classification of hypoglycaemia:
Hypoglycaemic epi[INVESTIGATOR_36238]-treatment observation period 
only.
Treatment-emergent: hypoglycaemic epi[INVESTIGATOR_36239]-emergent if the onset of 
the epi[INVESTIGATOR_36240]-treatment observation period (see definition of observation periods 
in Figure 17–2 ).
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_36241] 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_36242] (see Figure 17–2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)50. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG-confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
Severe or BG-confirmed symptomatic hypoglycaemia: An epi[INVESTIGATOR_36243]37or BG-confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with 
symptoms consistent with hypoglycaemia. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 109 of 132
ADA classification of hypoglycaemia37
!Severe hypoglycaemia: An epi[INVESTIGATOR_36244], glucagon, or take other corrective actions. PG concentrations may not be 
available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low plasma glucose
concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_36246] a measured plasma glucose concentration ≤ 3.9 mmol/L 
(70 mg/dL).
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured plasma glucose concentration > 3.9 
mmol/L (70 mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_36248] a plasma glucose determination but that was presumably caused by a 
plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 110 of 132
Hypoglycaemic 
epi[INVESTIGATOR_36249] ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_36250]/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–2 ADA classification of hypoglycaemia
PG: plasma glucose. SMPG: Self-measured plasma glucose
Data on treatment-emergent hypoglycaemic epi[INVESTIGATOR_36251], the percentage of subjects with at least one epi[INVESTIGATOR_1865] (%), the total 
number of epi[INVESTIGATOR_36252] [ADDRESS_36142]’s on-treatment observation period as 
offset. The model will include treatment and region as fixed factors and baseline HbA 1cas 
covariate.
The binary endpoint showing whether a subject has at least one treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36253] a logistic regression model with treatment and region as fixed factors and baseline HbA
1cas covariate.
17.5 Interim analysis 
No interim analyses will be performed before the database is locked.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 111 of 132
17.6 Health economics and/or patient reported outcomes (PROs)
Change from baseline to week 26 and week 52 in:
!DTSQs: individual items and treatment satisfaction score (6 of the 8 items summed)
The PRO endpoint will be evaluated using the primary analysis for the primary estimand based on 
FAS using the in-trial observation period and using the primary analysis for the secondary estimand 
based on FAS using the on-treatment without rescue medication period. The individual items and 
the treatment satisfaction score will be analysed separately as the other continuous efficacy 
endpoints with the associated baseline response as a covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36143] been gastrointestinal disorders (nausea, vomiting, diarrhoea, dyspepsia 
and constipation). Clinical trials have indicated that a low starting dose and gradual dose escalation 
mitigates the risk of gastrointestinal AEs. Consequently, a low starting dose and dose escalation 
with [ADDRESS_36144] that rodents are more sensitive to the mode of action of GLP-1 RAs 
for induction of C-cell tumours. However, as a precaution, subjects with a family or personal 
history of MEN 2 or MTC will not be enrolled in the trial. During the trial, calcitonin will be 
measured on a regular basis, and the guidance for investigators on further evaluation and action on 
elevated calcitonin concentrations is included in appendix A . 
Acute pancreatitis
Acute pancreatitis has been reported in subjects treated with GLP-1 RAs including oral 
semaglutide. As a precaution, subjects with a history of acute or chronic pancreatitis will not be 
enrolled in the trial. Also, subjects will be informed about the symptoms of acute pancreatitis and 
serum levels of lipase and amylase will be monitored throughout the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36145](s) or related products 
will not be enrolled in the trial. In addition, subjects will be instructed to contact [CONTACT_36339][INVESTIGATOR_1884] a hypersensitivity reaction to the trial product 
occurs.
Hypoglycaemia
Based on current knowledge about the GLP-[ADDRESS_36146] also been associated with volume 
depletion. It is recommended to monitor renal function and for signs and symptoms of fluid loss during therapy. Severe dehydration may be a risk factor for ketoacidosis.
Impaired renal function may increase the risk of metformin associated lactic acidosis when GLP-1 
RAs are co-administered with metformin. As a precaution, serum creatinine will be measured 
regularly. In subjects treated with metformin who experience prolonged or severe nausea and 
vomiting, the investigator should monitor serum creatinine, and if clinically indicated, withhold 
metformin until resolution of renal dysfunction.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 114 of 132
The use of the background medication should be in accordance with the current, approved labels.
Other safety considerations
Teratogenicity (embryo-foetal development toxicity)
Semaglutide caused embryo-foetal malformations in the rat through a GLP-[ADDRESS_36147] to ensure acceptable glycaemic control 
during the trial. If rescue medication is required, it should be in accordance with ADA/European 
Association for the Study of Diabetes27,28(excluding GLP-1 RAs, DPP-4 inhibitors and amylin 
analogues).
It is the responsibility of the investigator to ensure the best possible care according to the principles 
outlined in Diabetes Care [ADDRESS_36148] are described in the current edition of the IB for oral semaglutide (NN9924)
24or any updates thereto or in the current approved label of 
Victoza®.
[IP_ADDRESS] Liraglutide
The most commonly reported side effects associated with liraglutide are nausea, diarrhoea, 
vomiting, other GI symptoms, nasopharyngitis, hypoglycaemia (when combined with SU or 
insulin), anorexia, headache, increased heart rate, dizziness, rash and injection site reactions. Also, 
dehydration, renal impairment and pancreatitis have been reported52.
[IP_ADDRESS] Placebo
There will be strict glycaemic rescue criteria in place to ensure acceptable glycaemic control for all 
treatment arms at all times during the trial. Subjects will in case of unacceptable, persistent 
hyperglycaemia be offered treatment intensification (rescue medication) at the discretion of the 
investigator. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 115 of 132
18.1.2 Benefits 
In this trial, subjects will be randomised in a 2:2:1 manner to either oral semaglutide, liraglutide or 
placebo as add-on to their current background medication (metformin alone or metformin in 
combination with a SGLT-2 inhibitor). Subjects will therefore, for the majority of the trial period, 
be treated with a regime anticipated to be better than or equal to the treatment they receive at the 
time of entry into the trial. Based on the results of the phase [ADDRESS_36149] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP
1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigator must give the subject verbal and written information about the trial and the procedures involved in a form that the subject can read and 
understand.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36150]’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner and a revised 
written subject information must be provided and a new informed consent must be obtained.
In order to avoid missing data, the subjects will be informed about the importance of completing the 
trial also if the subjects discontinue from trial product.
18.[ADDRESS_36151]’s data will be handled 
as follows:
!Data already collected and any data collected at the end-of-trial visit including follow-up visit 
will be retained by [CONTACT_3454], entered into the database and used for the clinical trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_36152] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 117 of 132
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36153] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database. 
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor
trial master file.
19.[ADDRESS_36154] or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites. 
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_36340] (e.g. re-training of site staff).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36155] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36156] be available to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, any 
other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must include 
documented GCP training or a certificate)
!Signed receipt of IB for oral semaglutide and SmPC or similar product information for Victoza®
(liraglutide)
!Signed and dated Agreement on Protocol
!Signed and dated Agreement on Protocol Amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s site 
and Novo Nordisk
For Japan only: A seal is accepted as signature
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_36157] be completed and signed by [CONTACT_36342] 1572:
For US sites:
!Intended for US sites
!Conducted under the IND
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 121 of 132
By [CONTACT_36343], each investigator agrees to comply fully with ICH GCP1, 
applicable regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make
investigator's name [CONTACT_36374] [CONTACT_36344].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36158] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator's responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36159], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One or two investigators will be appointed by [CONTACT_36345] (signatory investigator) on behalf of all participating investigators. The signatory investigator 
will be appointed based upon the criteria defined by [CONTACT_36346]53.
23.[ADDRESS_36160] for 
Clinical Trial Disclosure4.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_36161] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 124 of 132
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038]. 
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication. 
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors53(sometimes referred to as the Vancouver 
Criteria). Novo Nordisk will appoint investigator(s) to prepare publications in collaboration with Novo Nordisk.
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than [ADDRESS_36162] their own research subjects' data, and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36163]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_36164].
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by [CONTACT_36348]. In any case trial files cannot 
be destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.[ADDRESS_36165]’s identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_18022], visit number and trial identification number. No direct identification of the subject 
will be stored together with the samples.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36166] the investigator if they wish to be informed about results derived from stored 
antibody samples obtained from their own body. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 127 of 132
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by [CONTACT_36349]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36167] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
German Drug Law dated August 24, 1976, last amended by [CONTACT_36350] 3 of the law dated December 10, 
2015 (Federal Law Gazette I p. 2210).
For Poland only: Novo Nordisk carries liability for the trial exclusively in the scope defined by [CONTACT_36351] 6 September
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators
are covered by [CONTACT_36352].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 129 of 132
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. 
Guideline for Good Clinical Practice E6(R1), Step 4. [ADDRESS_36168] amended by [CONTACT_941] 64th WMA General Assembly, Fortaleza, Brazil. October 2013.
3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53.
5. Chuang LM, Tsai ST, Huang BY, Tai TY, Diabcare-Asia Study G. The status of diabetes 
control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med. 2002;19(12):978-85.
6. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults 
with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102-4.
7. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. 
Mol Cell Endocrinol. 2009;297(1-2):127-36.
8. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913.9. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of 
the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(3):737-45.
10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-
insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
11. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 
(GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-8.
12. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in 
normal and diabetic sujbjects. J Clin Invest. 1967;46(12):1954-62.
13. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52(2):199-207.
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 
Nat Rev Endocrinol. 2012;8(12):728-42.
15. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide [ADDRESS_36169]. 1998;101(3):515-20.
16. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like 
peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
17. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of 
fasting hyperglycaemia by [CONTACT_36353]-lik e peptide 1 (7-36 amide) in type 2 (non-
insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-4.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 130 of 132
18. Nauck MA. Incretin-based therapi[INVESTIGATOR_36259] 2 diabetes mellitus: properties, functions, and 
clinical implications. Am J Med. 2011;124([ADDRESS_36170]):S3-18.
19. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. 
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-23.
20. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once 
weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
21. European Medicines Agency. ICH Topic M 3 (R2): Non-Clinical Safety Studies for the 
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, Step 3. July 2008.
22. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 
receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391-402.
23. Novo Nordisk A/S. Investigators Brochure for s.c. Semaglutide (NN9535), Edition 10 or 
any updates hereof. 2015.
24. Novo Nordisk A/S. Investigators Brochure for oral Semaglutide (NN9924), Edition 6 or any 
updates hereof. 2015.
25. EU label information Victoza, current version and any updates hereof.26. US label information Victoza, current version and any updates hereof.27. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
28. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
29. Novo Nordisk A/S. http://www.novonordisk-trials.com/website/content/how-we-disclose-
trial-information.aspx.
30. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
31. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007. 27 September 2007.
32. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of [ADDRESS_36171] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. 1 May 2001.
33. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: 131 of 132
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
34. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. Official Journal of the European Communities. December 2006.
35. Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: Bradley C, editor. Handbook 
of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994. p. 111-32.
36. National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 
Update. Am J Kidney Dis. 2012;60(5):850-86.
37. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
38. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
39. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009.
40. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-42.
41. Commission E. The Rules Governing Medicinal Products in the European Union, Volume 4, 
Annex 13, Investigational Medicinal Products. Brussels, February 2010.
42. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL, et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials (Draft). 20 Aug 2014.
43. KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international 
supplements. 2012;2(1):1-138.
44. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical 
approaches for multiple comparison procedures using weighted Bonferroni, Simes, or 
parametric tests. Biometrical Journal. 2011;53(6):894-913.
45. Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. [ADDRESS_36172] 2014.
46. Little RJA, Rubin DB. Statistical analysis with missing data: [LOCATION_001]: John Wiley & 
Sons. 1987.
47. Koch GG. Comments on 'Current issues in non-inferiority trials' by [CONTACT_19617] R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
48. (CHMP) EMACfMPfHU. Guideline on Missing Data in Confirmatory Clinical Trials 
(EMA/CPMP/EWP/1776/99 Rev. 1). 7/2/2010 2010.
49. National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT no.: 2015-005210-30 Page: [ADDRESS_36173]. 1987;79(3):777-81.
51. Standards of medical care in diabetes--2015: summary of revisions. Diabetes Care. 2015;[ADDRESS_36174]:S4.
52. Novo Nordisk A/S. Victoza
® (liraglutide), EU Summary of product characteristics (SmPc) 
(last updated 24/11/2015).
53. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 12/16/2014 
2014.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36175] be restricted to relevant 
parties.
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 2 of 6
1 Background
Treatment with GLP-1 receptor agonists has been shown to be associated with thyroid C-cell 
changes in rodents but not in non-human primates. The human relevance of this finding is 
unknown. However, based on the findings in rodents, monitoring of serum calcitonin (a sensitive 
biomarker for C-cell activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease.
There are several known confounding factors affecting calcitonin levels, e.g.:
!renal dysfunction
!smoking
!autoimmune thyroiditis
!several drug classes (e.g. proton pump inhibitors, beta-blockers, H 2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36176] has a calcitonin value ≥ 10 ng/L, the algorithm outlined in Figure 1 and described 
below should be followed. The algorithm applies for all calcitonin values in the trial.
Calcitonin < 10ng/L
Calcitonin  ≥ 10 ng/L and 
< 50 ng/L
Calcitonin  ≥ 50 ng/L and 
< 100 ng/L
Calcitonin  ≥ 100 ng/LEvaluation of 
calcitonin results
Calcitonin  ≥ 10 ng/L and 
last measurement in the 
trialNo action
●Investigate potential confounding 
factors
●Continue sampling of calcitonin 
according to protocol
●Refer to thyroid specialist
●Discontinue trial product
●Refer to thyroid specialist
●Refer to thyroid specialist
Figure 1 Flow of calcitonin monitoring
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject must immediately be referred to a thyroid specialist for further evaluation and 
the trial product must be discontinued (see protocol Section 6.5premature discontinuation of trial CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36177]). The subject should remain in the trial; however, all medications suspected to relate to this 
condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease1. All of these patients were diagnosed with MTC, resulting in a positive predictive 
value of 100 %.
Diagnostic evaluation should include:
!thyroid ultrasound examination
!fine needle aspi[INVESTIGATOR_36260] > 1 cm 
!potentially, surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET proto-oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject should be referred to a thyroid specialist for further evaluation. The subject 
should remain in the trial and continuation on trial product should be based on the evaluation done 
by [CONTACT_36354]. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease1. Two of these subjects were diagnosed with MTC and two were diagnosed with 
C-cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!thyroid ultrasound examination 
!if available, and if there are no contraindications, a pentagastrin stimulation test should be done. 
For subjects with positive pentagastrin stimulation test, surgery should be considered.
!if pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspi[INVESTIGATOR_36261].
2.3 Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol.
If the value is from the last sample taken in the trial, the subject should be referred to a thyroid 
specialist for further evaluation.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 5 of 6
Background: Calcitonin values from 20–50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm with calcitonin in this range is extremely low.
For calcitonin values between 10-20 ng/L Costante et al.
1identified 216 (3.7%) patients. One 
patient out of the 216 had a subsequent basal (unstimulated) calcitonin value of 33 ng/L, and had C-
cell hyperplasia at surgery. Two other studies used a cut-off of calcitonin > 10 ng/L to screen for C-
cell disease, but they do not provide sufficient information on patients with basal CT > 10 and < 20 
ng/L to allow conclusions2, 3.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 6 of 6
3 References
1. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive 
value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450-5.
2. Scheuba C, Kaserer K, A m, drosten R. Sporadic hypercalcitoninemia: clinica and 
therapeutic consequences. Endocrine Related Cancer. 2009;16(1):243-53.
3. Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, et al. Histopathological 
and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic 
C-cell hyperplasia? Endocr Relat Cancer. 2007;14(2):393-403.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36178] be restricted to relevant 
parties.
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36179] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
oNote: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
oAccidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however, the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen, as judged by [CONTACT_093], although they did not necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10 × UNL
!Hepatic event:
oALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
oALT or AST > 3 × UNL and total bilirubin > 2 × UNL*
oHepatic event leading to trial product discontinuation 
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 3 × UNL and total bilirubin > 2 × UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
In case any of these events fulfil the criteria for an SAE, please report accordingly, see Section 
12.1.2.
Some of these events will undergo event adjudication by [CONTACT_36355] (EAC), 
please see Section 12.7.2 and Table 12- 1.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 3 of 9
Acute coronary syndrome
If an event of acute coronary syndrome (ranging from unstable angina pectoris to myocardial 
infarction) is observed during the trial, the following additional information must be reported if 
available: 
!Duration of symptoms
!Changes in ECG
!Collection of cardiac biomarkers
!Cardiac imaging
!Cardiac stress testing
!Angiography
!Use of thrombolytic drugs
!Revascularisation procedures 
Cerebrovascular event
If a cerebrovascular event (e.g. TIA, stroke) is observed during the trial, the following additional 
information must be reported if available: 
!Type of event (e.g. TIA, stroke)
!Contributing condition
!Neurologic signs and symptoms
!History of neurologic disease
!Imaging supporting the condition
!Treatment given for the condition
Heart failure
If an event of heart failure is observed during the trial, the following additional information must be 
reported if available: 
!Signs and symptoms of heart failure
!NYHA class
!Supportive imaging
!Supportive laboratory measurements
!Initiation or intensification of treatment for this condition
Pancreatitis
For all confirmed events of pancreatitis the following additional information must be reported if 
available:
!Signs and symptoms of pancreatitis
!Specific laboratory test supporting a diagnosis of pancreatitis:
!Imaging performed and consistency with pancreatic diseaseCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 4 of 9
!Treatment for and complications of the event
!Relevant risk factors for pancreatic disease
!Family history of pancreatic disease
Assessments in case of suspi[INVESTIGATOR_36262]. The onset of the pain may be swift, reaching maximum 
intensity within 30 min, is frequently unbearable, and characteristically persists for more than 24 
hours without relief1.The pain is often associated with nausea and vomiting. Physical examination 
usually reveals severe upper abdominal tenderness at times associated with guarding. 
In general, both amylase and lipase are elevated during the course of acute pancreatitis. The serum 
lipase may remain elevated slightly longer than amylase. The level of the serum amylase and/or 
lipase does not correlate with the severity of acute pancreatitis1. In general, serum lipase is thought 
to be more sensitive and specific than serum amylase in the diagnosis of acute pancreatitis. 
In case of suspi[INVESTIGATOR_36194], the trial product should promptly be interrupted (no 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is 
confirmed). Appropriate additional examinations must be performed, including local measurement 
of amylase and lipase. 
The diagnosis of acute pancreatitis requires two of the following three features2: 
!abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epi[INVESTIGATOR_36263])
!serum lipase activity (and/or amylase activity) at least three times greater than the upper normal 
limit
!characteristic findings of acute pancreatitis on imaging.
If acute pancreatitis is ruled out, trial product should be re-initiated.
If acute pancreatitis is confirmed, appropriate treatment and careful monitoring of the subject 
should be initiated. The subject must be discontinued from trial product (treatment discontinuation 
call in IWRS), but should remain in the trial (see Section 6.5 and 8.1.5 ).
Neoplasm
All events of neoplasms (excluding thyroid neoplasms, which will be reported under thyroid 
disease) must be reported during the trial and the following additional information must be reported 
if available:CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 5 of 9
!Type of neoplasm
!Symptoms leading to identification of event
!Diagnostic imaging
!Pathological examination results
!Treatment for the event
!Participation in screening programs
!Risk factors associated with the event
Thyroid disease
If an event of thyroid disease, including any thyroid neoplasms, is observed during the trial, the 
following additional information must be reported if available:
!History of thyroid disease
!Signs and symptoms leading to investigations of thyroid disease
!Specific laboratory tests describing thyroid function
!Diagnostic imaging performed and any prior imaging supporting the disease history 
!Pathologic examinations
!Treatment given for the condition
!Risk factors identified
!Family history of thyroid disease
Renal event 
If a renal event is observed during the trial, the following additional information must be reported if 
available:
!Signs and symptoms of renal failure
!Specific laboratory tests supporting the diagnosis 
!Imaging performed supporting the diagnosis
!Kidney biopsy results
!Risk or confounding factors identified including exposure to nephrotoxic agents
Hypersensitivity reactions
All events of hypersensitivity reactions must be reported and the following additional information
must be reported if available:
!Signs and symptoms associated with the event
!Time of appearance after administration of trial drug
!Relevant immunological tests performed
!Treatment given for the reaction
!Previous history of similar reactions
!Risk or confounding factors identifiedCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36180] but should remain in the trial (see Section 6.5
and 8.1.5).
If suspi[INVESTIGATOR_1884] a hypersensitivity reaction occurs, the subjects should be instructed to contact [CONTACT_36356].
To assist in the diagnostic evaluation it is recommended to draw a blood sample for measurement of 
tryptase (total and/or mature tryptase, local assessment) within [ADDRESS_36181] but should remain in the trial (see Section 6.5and 8.1.5 ). It is recommended to draw a 
blood sample for local assessment of complement levels (C3 and C4) to assist in the diagnostic 
evaluation. Complement level results should be included in the specific event form when reporting 
the AE.
Acute gallstone disease
If an event of acute gallstone disease or clinical suspi[INVESTIGATOR_36264], the 
following additional information must be reported if available: 
!Signs and symptoms of acute gallstone disease
!Specific laboratory tests supporting a diagnosis of gallstone
!Imaging performed and consistency with gallstone disease
!Treatment given for the condition
!Relevant risk factors for acute gallstone disease
!Family history of gallstones
Medication error 
If a medication error is observed during the trial, the following additional information is required 
and must be reported: 
!Trial product(s) involved 
!Classification of medication error
oWrong drug(s) administered
oAdministration of an overdoseCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 7 of 9
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error 
For definition of medication error, see Section 12.1.[ADDRESS_36182] 
be reported if available:
!Signs and symptoms of lactic acidosis
!Specific laboratory tests describing the event 
!Possible cause(s) of the event
Creatine kinase (CK) > 10 × UNL
If an event of CK > 10 × UNL is observed during the trial, the following additional information 
must be reported if available:
!Signs and symptoms associated with the event 
!Recent physical activity
!Possible cause(s) of the event
Assessments in case of increased levels of creatine kinase
In case of CK > 10 × upper limit of normal (UNL), prompt repeat testing (at central laboratory) of 
CK should be done. Repeat testing (at central laboratory) should be done regularly until CK levels 
return to normal or baseline state. Additional clinical information should be gathered to seek the 
possible cause of the observed CK elevation. 
Hepatic event
!ALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
!ALT or AST > 3 × UNL and total bilirubin > 2 × UNL*
!Hepatic event leading to trial product discontinuation 
If one of the above events is observed during the trial, the following additional information must be 
reported if available:
!Signs and symptoms associated with the event 
!Risk factors
!Relevant laboratory test results 
!Diagnostic imaging performed 
!Possible cause(s) of the event CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 8 of 9
Assessments in case of increased levels of aminotransferases
Both events should prompt repeat testing (at the central laboratory) including ALT, AST, ALP and 
total bilirubin, and discontinuation of trial product should be considered. Thereafter, repeat testing 
(at the central laboratory) of ALT, AST, ALP and total bilirubin should be done regularly until the 
abnormalities return to normal or baseline state. Additional clinical information such as related 
symptoms, risk factors and contributing conditions (e.g. viral hepatitis, autoimmune hepatitis, 
alcoholic hepatitis, hepatobiliary or pancreatic disorders) should be gathered to seek a possible 
cause of the observed laboratory test abnormalities.
*Please note that risk of liver injury defined as ALT or AST > 3 × UNL and total bilirubin > 2 ×
UNL, where no alternative aetiology exits (Hy’s law), should also be reported as a SAE (important 
medical event, according to section 12.1.2 ).CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 02 March 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 9 of 9
References: 
1. Banks PA, Freeman ML, Practice Parameters Committee of the American College of G. 
Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.
2. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut. 2013;62(1):102-11.
3. Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for 
Therapeutic Protein Products. August 2015.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide
Trial ID: NN9924-4224Clinical Trial Report
Appendix 16.1.129 October 2018
1.0
FinalCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 1 of 21
Protocol Amendment
no 1
to Protocol, final version 1.0
dated 02 March 2016
Trial ID: NN9924-4224
PI[INVESTIGATOR_15597] 4 – vs. GLP-1 RA
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects 
with Type 2 Diabetes Mellitus
Trial phase: 3a
Applicable to all countries 
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 2 of 21
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
Table of Figures............................................................................................................... .................................3
Table of Tables................................................................................................................ ..................................3
1 Introduction including rationale for the protocol  amendment .............................................................4
1.1 Additional eye examinations and additional data collection on diabetic retinopathy....................4
1.2 Addition of bicarbonate as a part of th e biochemistry laborato ry assessment...............................4
1.3 Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications .............................................................................................................. ............[ADDRESS_36183] to follow-up..............................5
1.5 Minor adjustments, clarifications a nd correction of t ypographical errors .....................................5
1.5.1 Inclusion criteria ........................................................................................................ ..5
1.5.2 Statistical considerations..............................................................................................5
1.5.3 Adverse events for Adjudication .................................................................................5
1.5.4 Clarifications............................................................................................................ ....6
2 Changes ....................................................................................................................... ...............................7
2.1 Section 2  Flow chart ....................................................................................................... ..............7
2.2 Section [IP_ADDRESS] Supportive seconda ry safety endpoints.................................................................[ADDRESS_36184] admin istration....................................................10
2.6 Section 8.1.4 Phone contacts ................................................................................................ .......10
2.7 Section 8.1.5 End-of-treatment (visit 13) and Follow-up (visit 14).............................................[ADDRESS_36185] and Follow-up (visits 13A and 
14A) ........................................................................................................................... ..................11
2.9 Section [IP_ADDRESS] Lost to follow-up .................................................................................................11
2.10 Section [IP_ADDRESS] Adverse events re quiring additional data collection...........................................12
2.11 Section 8.4.2   P hysical examination ....................................................................................... ....13
2.12 Section 8.4.4  Eye examination............................................................................................. .......13
2.13 Section 8.4.6 Laboratory assessments for safety .........................................................................13
2.14 Section 8.4.8 Anti-semaglutide antibodies .................................................................................. 14
2.15 Section 8.4.9  Hypoglycaemic epi[INVESTIGATOR_1841] ...................................................................................... 14
2.16 Section 12.1.5 Adverse events requi ring additional data collection ............................................15
2.17 Section 12.2 Reporting of adverse events................................................................................... .15
2.18 Section 12.7.2 Event ad judication committee..............................................................................15
2.19 Section 17.2  Definition of analysis sets.................................................................................. ....15
2.20 Section 17.3.1 Primary analysis for the primary estimand ..........................................................16
2.21 Section [IP_ADDRESS] Continuous e fficacy endpoints..........................................................................16
2.22 Section [IP_ADDRESS]  Safety endpoints......................................................................................... ......17
2.23 Section 18.1.1  Risk s and precautions ...................................................................................... ...17
2.24 Section 18.1.1  Risk s and precautions ...................................................................................... ...18
2.25 Section 27  References..................................................................................................... ............18CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 3 of 21
2.26 Appendix B, Section 1 Adverse Events re quiring additional data collection..............................19
2.27 Appendix B  New Section to be  added to the appendix: .............................................................21
Table of Figures   
Page
No table of figures entries found.
Table of Tables   
Page
No table of figures entries found.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 4 of 21
1 Introduction including rationale for the protocol amendment
This protocol amendment introduces:
1. Additional eye examinations and additional data collection on diabetic retinopathy 
2. Addition of bicarbonate as a part of the biochemistry laboratory assessment
3. Investigator’s responsibility in ensuring evaluation and management of certain risk factors and 
complications
4. Clarification of the criteria for completion, withdrawal and lost to follow-up
5. Other minor corrections and clarifications
1.1 Additional eye examinations and additional data collection on diabetic retinopathy 
Updated protocol Sections: 2, [IP_ADDRESS], [IP_ADDRESS], 8.4.4, 12.1.5, 17.2, 17.3.1, [IP_ADDRESS], 18.1.[ADDRESS_36186] 
been implemented in all trials in the PI[INVESTIGATOR_36181]. Also, to further understand this safety 
signal, additional information will be collected for all diabetic retinopathy events reported during 
the trial. The information will be collected not only from new subjects enrolled by [CONTACT_36357], but also from already enrolled subjects to the extent that the information is available. 
Furthermore, information to the investigators and subjects related to diabetic retinopathy has been 
added to the protocol (see Section 18) and the subject information. 
1.2 Addition of bicarbonate as a part of the biochemistry laboratory assessment
Updated protocol Section: 8.4.[ADDRESS_36187] been associated with 
a risk for metabolic acidosis.
1.3 Investigator’s responsibility in ensuring evaluation and management of certain risk 
factors and complications
Updated protocol Section: 8.4.2CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 5 of 21
 text is added to highlight the investigator’s responsibility in 
relation to further evaluation of potential incidental thyroid nodules discovered at the physical 
examination.
In addition, text is added to highlight the investigator’s responsibility in ensuring evaluation and 
management of cardiovascular risk factors and microvascular complications such as diabetic kidney 
disease and diabetic retinopathy.
1.[ADDRESS_36188] to follow-up
Updated protocol Sections: 6.6, 8.1.5, 8.1.6 and [IP_ADDRESS].
The criteria for subject completion, -withdrawal and -lost to follow-up respectively are clarified and 
have been made consistent across Sections. Lost to follow-up is considered a subcategory to 
withdrawal from trial. In addition, it is emphasised that as soon as contact [CONTACT_1639] a subject is lost, efforts 
must be made to regain contact [CONTACT_36358].
Only if contact [CONTACT_36359]. 
Because this trial is not an outcome trial the terminology ‘health status’ is replaced with “relevant 
safety information”- the purpose of which is to follow up on any adverse events or pregnancy, and 
not to determine if a subject completes the trial or not.
1.5 Minor adjustments, clarifications and correction of typographical errors
1.5.1 Inclusion criteria
Updated protocol Section: 6.2
The wording of Inclusion criterion no. 5 in Section 6.2 will be aligned with the wording in the 
summary section.
1.5.2 Statistical considerations
Updated protocol Sections: 17.3.1 and [IP_ADDRESS].
For the pattern mixture model using multiple imputations, the number of imputations will be 
increased from 100 to 1000 data sets, to ensure a greater precision of the estimates. In addition, an 
error in the number of groups used for imputations is corrected.
1.5.3 Adverse events for Adjudication
Updated protocol Section: 12.7.2
Table 12-2 has been aligned with Table 12-1 reflecting that unstable angina pectoris (UAP) requires
hospi[INVESTIGATOR_36265].CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 6 of 21
1.5.4 Clarifications
Updated protocol Sections: 8.1.3, 8.1.4, 8.4.[ADDRESS_36189].
Wording deleted regarding hypoglyc aemic epi[INVESTIGATOR_1841], as it is included in “medication errors”.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 7 of 21
2 Changes
2.1 Section 2 Flow chart
Trial PeriodsScree
ningaRandomisa-
tion TreatmentEnd-of-
treatment 
(EoT) Follow-upbEoT 
premature 
disconti-
nuationcFollow-up 
premature 
discontinua-
tionc
Visit (V), Phone (P) V1 V2 P3 V4 P5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V13A V14A
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Timing of visit (weeks)Up to 
−[ADDRESS_36190] (last 
dose) 
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_36191] RELATED
INFO/ASSESSMENTS
PRO questionnaire x x x x
SAFETY
Eye examination xdxdxd
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 8 of 21
Footer Description
xdDilated fundoscopy/fundus photography performed within [ADDRESS_36192] examination.
Dilated fundoscopy/fundus photography must be performed again:
!at V13 or within 5 weeks thereafter for subjects completing treatment
!at V13A or within [ADDRESS_36193]
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 9 of 21
2.2 Section [IP_ADDRESS] Supportive secondary safety endpoints
Change from baseline to week 26 and 52 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination (week 52 only)
!Eye examination category (week 52 only)
2.3 Section 6.2 Inclusion criteria
5. Stable daily dose of metformin ( ≥[ADDRESS_36194]) alone or in combination with a stable daily dose of a SGLT-2 inhibitor (all 
doses approved as maintenance therapy) ≥for at least 90 days prior to the day of screening (fixed-
dose combinations are allowed) .
2.[ADDRESS_36195]’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial. A subject who does not complete the trial is also considered withdrawn from 
the trial. Hence a subject is considered withdrawn if the following applies: 
!Subject withdrew consent
!Subject is lost to follow up (only to be used if there is no contact [CONTACT_36360]’s last scheduled visit, see Sections 8.1.7 and 8.1.8
!Other (subject deceased or closure of trial site)CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36196] be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All V2 assessments must be performed before administration of first dose of trial product.
Instruct and remind the subject to escalate the dose of liraglutide/placebo after week 1.
2.6 Section 8.1.4 Phone contacts
The phone contacts should be conducted as outlined in the flowchart (see Section 2).
At V2, the investigator should instruct the subject to dose escalate liraglutide/liraglutide placebo to 
1.[ADDRESS_36197] (P3), the 
investigator should follow-up on compliance and potential technical issues regarding the dose 
escalation that was done by [CONTACT_36285]. At P3, the subject will be 
instructed to dose escalate to 1.8 mg once-daily. At P5, the investigator should follow-up on 
compliance and reporting of adverse events (AEs) with special focus on preventing dehydration in 
case of severe gastrointestinal AEs.
2.7 Section 8.1.5 End-of-treatment (visit 13) and Follow-up (visit 14)
At V13 the subject should be reminded about the importance of attending the follow-up visit (V14). 
If the subject, nonetheless, does not attend V14, the site should make efforts to obtain contact [CONTACT_36361]. 
A trial completer is defined as a subject who attends, or is in contact [CONTACT_36362], at the subject’s 
last scheduled visit. For subjects who complete treatment, the last scheduled visit is V14. (For 
subjects who discontinue trial product, see Section 8.1.6).
In case the subject cannot be reached (by [CONTACT_36286]) at the scheduled visit 14, the 
site should consult the contacts provided by [CONTACT_423] (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow up and this should 
be specified in the end-of-trial form.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36198] and Follow-up (visits 
13A and 14A)
Subjects should continue with the originally scheduled site contacts after V13 4A and up to and 
including V13. If necessary, in order to retain the subject in the trial, site visits can be replaced by 
[CONTACT_36287] V14A. However, if a subject is unable or unwilling to attend all subsequent 
visit(s), the investigator should at least aim to have the subject attend V9 (week 26) and the End-of-
treatment visit (V13) (week 52) as these visits should be performed for all subjects, if at all possible 
(except subjects who withdraw informed consent, see Section 8.1.7). 
Subjects, who only agree to attend or provide health status at the planned V12, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by [CONTACT_36288]) at the scheduled V12, the site should consult the contacts provided by [CONTACT_423] (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow-up and this should be specified in the end of trial form.
A subject who prematurely discontinued trial product is still considered a trial completer if the 
subject attends or is in contact [CONTACT_36362], at the subject’s last scheduled visit. For subjects who 
prematurely discontinue trial product, the last scheduled visit is V13 (or V14A if it is scheduled 
after V13). The site should in due time prepare for establishing contact [CONTACT_36363] V9 and V13, respectively if the subject has agreed to attend these 
visits. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact [CONTACT_36364] (for withdrawal procedures, see 
Section 8.1.7).
2.9 Section [IP_ADDRESS] Lost to follow-up
In case contact [CONTACT_36365], the site should immediately undertake efforts to 
re-establish contact. If the subject cannot be reached (by [CONTACT_36286]) and the 
subject has consented to it, the site should consult the contacts provided by [CONTACT_423] (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) in an attempt to regain contact [CONTACT_36366]. Efforts to regain contact [CONTACT_36367]’s last scheduled 
visit: V14 for subjects who have completed treatment, whereas for subjects who have discontinued 
trial product prematurely the last visit is V13 (or V14A if it is scheduled after V13). Only if contact [CONTACT_36368]: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: [ADDRESS_36199] to follow up (see Section 6.6).
2.10 Section [IP_ADDRESS] Adverse events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36266])
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event defined as:
- ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
- ALT or AST > 3x UNL and total bilirubin > 2x UNL*
- Hepatic event leading to trial product discontinuation.
!Diabetic retinopathy and related complications
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 3x UNL and total bilirubin > 2x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no other seriousness criteria are applicable.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 13 of 21
2.11 Section 8.4.2 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
Section 2 and 8.1.8). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland *
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
*Please note that the diagnostic evaluation of thyroid nodules should be in accordance with the 
American Thyroid Association Management Guidelines or any updates hereof35, and adapted to 
local treatment guidelines if applicable.
2.12 Section 8.4.4 Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by [CONTACT_36369]. Fundoscopy requires pharmacological dilation of both 
pupi[INVESTIGATOR_8324]. Results of the dilated fundoscopy/fundus photography will be interpreted by [CONTACT_093] 
(see Section 8.1.8).
2.13 Section 8.4.6 Laboratory assessments for safety
Biochemistry:
!Alanine aminotransferase (ALT)
!Albumin
!Alkaline phosphatase (ALP)
!Amylase
!Aspartate aminotransferase (AST)
!Bilirubin, total
!Calcium, total
!Creatinine
!eGFR per CKD-EPI36
!Creatine kinase (CK)
!LipaseCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 14 of 21
!Potassium
!Sodium
!Urea
!Bicarbonate
2.[ADDRESS_36200] 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
[CONTACT_36370] .
2.15 Section 8.4.9 Hypoglycaemic epi[INVESTIGATOR_36267] "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-
medical person)?
!Where the treatment was administered (in clinic/emergency room/ hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an 
ambulance or not)
!Type of treatment provided by [CONTACT_19015] (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), miscalculation of dose of anti-diabetic medication, other factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms38
- Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
- Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
- General malaise: headache or malaise (feeling discomfort/unease)
!Other symptomsCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 15 of 21
2.16 Section 12.1.5 Adverse events requiring additional data collection
Table 12-1 Adverse events requiring completion of specific event forms and/or are subject to 
event adjudication
Event Specific event form Event adjudication
Diabetic retinopathy and related complications Yes No
2.17 Section 12.2 Reporting of adverse events
Novo Nordisk A/S assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference
documents: 
!IB for oral Semaglutide (NN9924)24and Victoza ®; current versions and any updates 
thereto.
!CCDS (Company Core Data Sheet) for Victoza ®Liraglutide; current versions and any 
updates thereto. 
2.18 Section 12.7.2 Event adjudication committee
Table 12 2 Adverse events for adjudication
Events Description Adjudication outcome
Acute Coronary Syndrome !Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP ) requiring 
hospi[INVESTIGATOR_11956]!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospi[INVESTIGATOR_11956]
2.19 Section 17.2 Definition of analysis sets
On-treatment : This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs , eye examination category , anti-
semaglutide antibodies, and AEs including hypoglycaemic epi[INVESTIGATOR_1841], the observation period ends at 
the first date of any of the following:CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 16 of 21
!the follow-up visit (V14)
!the follow-up prematurely discontinuation visit (V14A)
!the last date on trial product +38 days (5 weeks follow-up period + 3 days visit window)
!the end-date for the in-trial observation period
2.20 Section 17.3.1 Primary analysis for the primary estimand 
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with stratification factor and region as categorical fixed 
effects and baseline HbA 1cmeasurement as a covariate will be fitted to observed values of the 
change from baseline in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_36201] with missing week 26 data based on stratification factor and region as categorical 
and baseline HbA 1c. Thus, 100 1000 complete data sets will be generated including observed 
and imputed values.
Analysis used for confirming superiority versus placebo/liraglutide at week 26:
For each of the 100 1000 (now complete) imputed data sets, the change from baseline to week 26 
will be analysed using an ANCOVA with treatment, stratification factor and region as categorical 
fixed effects and baseline HbA 1cas covariate. The results obtained from analysing the datasets will 
be combined using Rubin’s rule46to draw inference.
2.21 Section [IP_ADDRESS] Continuous efficacy endpoints
For evaluation of the primary estimand the analyses will be performed separately for week [ADDRESS_36202] or initiated rescue medication prior to week 26 
or at/or after week 26. This will result in imputation of missing data within [ADDRESS_36203] available data in one of the 12 9groups, the imputation will be made within the 6
groups specified for the primary evaluation. The frequency of missing data is expected to be slightly 
larger at week 52 compared to week 26. The rate of missing data is expected to decline over time.
Binary efficacy endpoints
The above eight binary endpoints will be analysed using a logistic regression model with treatment ,
stratification factor and region as fixed effects and baseline response as covariate (i.e. baseline 
HbA1c for binary HbA1c endpoints, baseline weight for weight endpoints and both baseline HbA1c 
and baseline weight for the binary endpoint that combines both parameters). To account for missing data, the analysis will be made using a sequential multiple imputation approach as described below:CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 17 of 21
!Multiple imputed data sets (100 1000 ) will be created in which missing values for the 
underlying continuous assessments are imputed by [CONTACT_36371]/rescue status assuming MAR and as described in Section 17.3.1 for the primary 
estimand and by [CONTACT_36372] 17.3.2 for the 
secondary estimand.
!The binary endpoint will be created for each of the 100 1000 complete data sets
Each of the created complete data set will be analysed with the logistic model and inference will be 
drawn using Rubin’s rule46.
2.22 Section [IP_ADDRESS] Safety endpoints
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination (week 52 only)
!Eye examination category (week 52 only) 
2.[ADDRESS_36204] a fundus photography or dilated CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 18 of 21
fundoscopy performed before enrolment into the trial; moreover, subjects with proliferative 
retinopathy or maculopathy requiring acute treatment will be excluded. As part of good diabetes 
management the investigator is encouraged to ensure adequate monitoring and treatment of
diabetic retinopathy in subjects enrolled into the trial57.
2.[ADDRESS_36205]. This 
includes adequate glycaemic control, appropriate risk factor modification such as optimal 
treatment of hypertension, dyslipi[INVESTIGATOR_36268], as well as regular 
monitoring and treatment of diabetic kidney disease and diabetic retinopathy57. 
2.25 Section 27 References
The reference numbers will change throughout the updated protocol when below new references are 
introduced
35. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 
American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
51. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid 
tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-5.
52. The Diabetes Control and Complications Trial Research Group. Early worsening of 
diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874-86.
53. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic 
control with GLP-[ADDRESS_36206]. 2014;103(3):e37-9.
54. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53, Erratum 1999; 354: 602.
55. The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye 
Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 19 of 21
Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Follow-On Study. Diabetes Care. 2016;39(7):1089-100.
56. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
57. American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes 
Care. 2016;39 (Suppl. 1):S1-S109. 
2.[ADDRESS_36207] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
oNote: Use of wrong DUN is not considered a medication error.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
oAccidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however, the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen, as judged by [CONTACT_093], although they did not necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10 × UNL
!Hepatic event:
oALT or AST > 5 × UNL and total bilirubin ≤ 2 × UNL
oALT or AST > 3 × UNL and total bilirubin > 2 × UNL* 
oHepatic event leading to trial product discontinuation 
!Diabetic retinopathy and related complicationsCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 20 of 21CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4224 Version: 1.0
UTN: U1111-1176-6029 Status: Final
EudraCT No.: 2015-005210-30 Page: 21 of 21
2.27 Appendix B New Section to be added to the appendix:
Diabetic retinopathy and related complications
If an event of diabetic retinopathy or related complications is observed during the trial the 
following additional information must be reported, if available:
!Signs and symptoms associated with the event
!Results of the eye examination 
!Treatment for and complications of the event
!Contributing conditionsCONFIDENTIAL